0000313927--12-31 7.2 P20Y http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent P20Y http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent Q3 P2Y 7.1 http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent false P2Y http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent 107.0 P2Y http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent 0000313927 chd:ArmandProductsCompanyMember 2022-09-30 0000313927 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-09-30 0000313927 2021-09-30 0000313927 us-gaap:BuildingAndBuildingImprovementsMember 2021-12-31 0000313927 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember chd:TwoPointEightSevenFivePercentSeniorNotesDueOctoberOneTwoThousandAndTwentyTwoMember 2021-12-31 0000313927 chd:FlawlessTradenameMember 2022-09-30 0000313927 us-gaap:TreasuryStockMember 2022-09-30 0000313927 us-gaap:MachineryAndEquipmentMember 2021-12-31 0000313927 us-gaap:OperatingSegmentsMember chd:ConsumerDomesticMember chd:PersonalCareProductsMember 2022-01-01 2022-09-30 0000313927 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-09-30 0000313927 chd:TwoPointFourFivePercentSeniorNotesDueAugustOneTwoThousandAndTwentyTwoMember us-gaap:FairValueInputsLevel2Member 2022-09-30 0000313927 chd:TwoPointFourFivePercentSeniorNotesDueAugustOneTwoThousandAndTwentyTwoMember 2022-09-30 0000313927 2021-12-31 0000313927 srt:MinimumMember chd:ZicamAcquisitionMember 2020-12-03 2020-12-31 0000313927 2022-01-01 2022-06-30 0000313927 chd:TwoPointsThreePercentSeniorNotesDueDecemberFifteenTwoThousandAndThirtyOneMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-09-30 0000313927 chd:TwoPointEightSevenFivePercentSeniorNotesDueOctoberOneTwoThousandAndTwentyTwoMember 2021-12-31 0000313927 chd:ZicamAcquisitionMember chd:ConsumerInternationalMember 2021-12-31 0000313927 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-12-31 0000313927 2022-10-26 0000313927 us-gaap:CarryingReportedAmountFairValueDisclosureMember chd:TermLoanDueInDecemberTwentyTwoTwoThousandAndTwentyFourMember 2021-12-31 0000313927 chd:ZicamAcquisitionMember 2021-12-31 0000313927 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-12-31 0000313927 chd:TwoPointFourFivePercentSeniorNotesDueAugustOneTwoThousandAndTwentyTwoMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-09-30 0000313927 chd:CommercialBankMember 2021-02-01 2021-02-28 0000313927 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0000313927 chd:ArmaKleenCompanyMember 2021-01-01 2021-09-30 0000313927 chd:ThreePointOneFivePercentSeniorNotesDueAugustOneTwoThousandAndTwentySevenMember 2022-09-30 0000313927 chd:TheraBreathAcquisitionMember 2022-09-30 0000313927 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0000313927 us-gaap:CommonStockMember 2020-12-31 0000313927 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000313927 chd:ArmandProductsCompanyMember 2021-09-30 0000313927 chd:FlawlessAcquisitionMember 2021-12-31 0000313927 us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember 2022-09-30 0000313927 us-gaap:EnergyRelatedDerivativeMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000313927 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000313927 chd:ArmandProductsCompanyAndArmaKleenCompanyMember 2021-01-01 2021-09-30 0000313927 us-gaap:RetainedEarningsMember 2022-06-30 0000313927 chd:TwoPointFourFivePercentSeniorNotesDueAugustOneTwoThousandAndTwentyTwoMember 2022-01-01 2022-09-30 0000313927 us-gaap:EquityContractMember us-gaap:NondesignatedMember 2022-09-30 0000313927 us-gaap:LandMember 2022-09-30 0000313927 us-gaap:NondesignatedMember us-gaap:ForeignExchangeContractMember 2021-12-31 0000313927 chd:HeroAcquisitionMember 2022-08-31 2022-08-31 0000313927 chd:HeroAcquisitionMember 2022-08-31 0000313927 us-gaap:OperatingSegmentsMember 2022-07-01 2022-09-30 0000313927 us-gaap:TreasuryStockMember 2022-07-01 2022-09-30 0000313927 chd:ThreePointNineFivePercentSeniorNotesDueAugustOneTwoThousandAndFortySevenMember 2022-01-01 2022-09-30 0000313927 2021-01-01 2021-03-31 0000313927 chd:ArmaKleenCompanyMember 2021-09-30 0000313927 us-gaap:CarryingReportedAmountFairValueDisclosureMember chd:ThreePointNineFivePercentSeniorNotesDueAugustOneTwoThousandAndFortySevenMember 2021-12-31 0000313927 chd:TwoPointFourFivePercentSeniorNotesDueAugustOneTwoThousandAndTwentyTwoMember 2021-12-31 0000313927 us-gaap:RetainedEarningsMember 2022-03-31 0000313927 us-gaap:OperatingSegmentsMember chd:ConsumerDomesticMember chd:PersonalCareProductsMember 2021-07-01 2021-09-30 0000313927 chd:CommercialBankMember 2021-12-31 0000313927 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-12-31 0000313927 chd:TwoPointEightSevenFivePercentSeniorNotesDueOctoberOneTwoThousandAndTwentyTwoMember 2022-09-30 0000313927 us-gaap:CorporateNonSegmentMember 2022-07-01 2022-09-30 0000313927 us-gaap:TreasuryStockMember 2022-01-01 2022-03-31 0000313927 chd:FivePointZeroZeroPercentageNotesDueJuneFifteenTwoThousandFiftyTwoMember 2021-12-31 0000313927 srt:MaximumMember chd:TheraBreathAcquisitionMember 2021-12-24 2021-12-24 0000313927 us-gaap:TradeNamesMember 2022-09-30 0000313927 us-gaap:TreasuryStockMember 2021-12-31 0000313927 us-gaap:TreasuryStockMember 2021-07-01 2021-09-30 0000313927 us-gaap:FairValueInputsLevel2Member chd:TwoPointEightSevenFivePercentSeniorNotesDueOctoberOneTwoThousandAndTwentyTwoMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-09-30 0000313927 chd:TwoPointsThreePercentSeniorNotesDueDecemberFifteenTwoThousandAndThirtyOneMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-12-31 0000313927 chd:TheraBreathAcquisitionMember 2021-12-23 2021-12-24 0000313927 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000313927 chd:TwoPointEightSevenFivePercentSeniorNotesDueOctoberOneTwoThousandAndTwentyTwoMember 2022-10-31 2022-10-31 0000313927 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0000313927 us-gaap:BuildingAndBuildingImprovementsMember 2022-09-30 0000313927 us-gaap:OperatingSegmentsMember chd:ConsumerDomesticMember chd:PersonalCareProductsMember 2021-01-01 2021-09-30 0000313927 chd:TradeNameAndOtherIntangibleAssetsMember 2022-09-30 0000313927 chd:InterestRateSwapLockMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000313927 us-gaap:OperatingSegmentsMember chd:ConsumerInternationalMember 2022-07-01 2022-09-30 0000313927 2022-03-31 0000313927 us-gaap:OperatingSegmentsMember chd:SpecialtyProductsDivisionMember 2021-01-01 2021-09-30 0000313927 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000313927 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-09-30 0000313927 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000313927 us-gaap:CarryingReportedAmountFairValueDisclosureMember chd:ThreePointOneFivePercentSeniorNotesDueAugustOneTwoThousandAndTwentySevenMember 2021-12-31 0000313927 us-gaap:TreasuryStockMember 2021-04-01 2021-06-30 0000313927 us-gaap:OperatingSegmentsMember 2021-01-01 2021-09-30 0000313927 chd:TermLoanDueInDecemberTwentyTwoTwoThousandAndTwentyFourMember 2022-09-30 0000313927 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-09-30 0000313927 us-gaap:CarryingReportedAmountFairValueDisclosureMember chd:TwoPointEightSevenFivePercentSeniorNotesDueOctoberOneTwoThousandAndTwentyTwoMember 2021-12-31 0000313927 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000313927 us-gaap:RetainedEarningsMember 2021-09-30 0000313927 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000313927 chd:TwoPointFourFivePercentSeniorNotesDueAugustOneTwoThousandAndTwentyTwoMember 2021-01-01 2021-12-31 0000313927 us-gaap:PatentsMember 2022-09-30 0000313927 us-gaap:CarryingReportedAmountFairValueDisclosureMember chd:ThreePointOneFivePercentSeniorNotesDueAugustOneTwoThousandAndTwentySevenMember 2022-09-30 0000313927 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000313927 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0000313927 chd:ZicamAcquisitionMember 2022-09-30 0000313927 chd:EvergreenProgramMember 2021-12-01 2021-12-31 0000313927 chd:ConsumerDomesticMember chd:TheraBreathAcquisitionMember 2022-01-01 2022-09-30 0000313927 us-gaap:CorporateNonSegmentMember 2021-01-01 2021-09-30 0000313927 us-gaap:FairValueInputsLevel2Member chd:ThreePointNineFivePercentSeniorNotesDueAugustOneTwoThousandAndFortySevenMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-12-31 0000313927 chd:TermLoanDueInDecemberTwentyTwoTwoThousandAndTwentyFourMember 2021-12-31 0000313927 chd:TheraBreathAcquisitionMember 2021-12-24 0000313927 us-gaap:TreasuryStockMember 2021-03-31 0000313927 us-gaap:FairValueInputsLevel2Member chd:ThreePointNineFivePercentSeniorNotesDueAugustOneTwoThousandAndFortySevenMember 2021-12-31 0000313927 us-gaap:FairValueInputsLevel2Member chd:ThreePointOneFivePercentSeniorNotesDueAugustOneTwoThousandAndTwentySevenMember 2022-09-30 0000313927 us-gaap:FairValueInputsLevel2Member chd:ThreePointOneFivePercentSeniorNotesDueAugustOneTwoThousandAndTwentySevenMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-09-30 0000313927 us-gaap:OperatingSegmentsMember 2022-01-01 2022-09-30 0000313927 chd:ZicamAcquisitionMember 2022-01-01 2022-09-30 0000313927 us-gaap:PatentsMember 2021-12-31 0000313927 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0000313927 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-12-31 0000313927 us-gaap:OperatingSegmentsMember chd:SpecialtyProductsDivisionMember 2022-01-01 2022-09-30 0000313927 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000313927 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-12-31 0000313927 chd:ThreePointNineFivePercentSeniorNotesDueAugustOneTwoThousandAndFortySevenMember 2021-12-31 0000313927 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000313927 chd:TradeNameAndOtherIntangibleAssetsMember 2022-01-01 2022-09-30 0000313927 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-09-30 0000313927 us-gaap:OperatingSegmentsMember 2021-07-01 2021-09-30 0000313927 2022-04-01 2022-06-30 0000313927 chd:ThreePointOneFivePercentSeniorNotesDueAugustOneTwoThousandAndTwentySevenMember 2022-01-01 2022-09-30 0000313927 2021-04-01 2021-06-30 0000313927 us-gaap:OperatingSegmentsMember chd:ConsumerDomesticMember 2022-01-01 2022-09-30 0000313927 chd:TwoPointFourFivePercentSeniorNotesDueAugustOneTwoThousandAndTwentyTwoMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0000313927 us-gaap:FairValueInputsLevel2Member chd:FivePointZeroZeroPercentSeniorNotesDueJuneFifteenTwoThousandFiftyTwoMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-09-30 0000313927 chd:ArmaKleenCompanyMember 2021-09-30 0000313927 us-gaap:RevolvingCreditFacilityMember 2022-06-16 0000313927 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000313927 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0000313927 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000313927 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-09-30 0000313927 us-gaap:OperatingSegmentsMember chd:ConsumerDomesticMember chd:PersonalCareProductsMember 2022-07-01 2022-09-30 0000313927 us-gaap:RetainedEarningsMember 2021-06-30 0000313927 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000313927 us-gaap:FairValueInputsLevel2Member chd:TermLoanDueInDecemberTwentyTwoTwoThousandAndTwentyFourMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-12-31 0000313927 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-09-30 0000313927 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0000313927 chd:ArmandProductsCompanyMember 2021-01-01 2021-09-30 0000313927 chd:TherabreathMember 2022-09-30 0000313927 srt:MaximumMember chd:TheraBreathAcquisitionMember 2021-12-23 2021-12-24 0000313927 chd:TwoPointFourFivePercentSeniorNotesDueAugustOneTwoThousandAndTwentyTwoMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-12-31 0000313927 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-09-30 0000313927 chd:TheraBreathAcquisitionMember chd:SpecialtyProductsDivisionMember 2022-01-01 2022-09-30 0000313927 chd:TwoPointsThreePercentSeniorNotesDueDecemberFifteenTwoThousandAndThirtyOneMember 2022-09-30 0000313927 chd:FlawlessAcquisitionMember chd:ConsumerInternationalMember 2021-01-01 2021-09-30 0000313927 us-gaap:TreasuryStockMember 2022-03-31 0000313927 chd:TwoPointsThreePercentSeniorNotesDueDecemberFifteenTwoThousandAndThirtyOneMember 2021-12-31 0000313927 chd:TwoPointFourFivePercentSeniorNotesDueAugustOneTwoThousandAndTwentyTwoMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-09-30 0000313927 us-gaap:TreasuryStockMember 2021-09-30 0000313927 chd:TwoPointEightSevenFivePercentSeniorNotesDueOctoberOneTwoThousandAndTwentyTwoMember 2022-10-01 0000313927 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000313927 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:InterestRateSwapMember 2022-09-30 0000313927 2022-07-01 2022-09-30 0000313927 chd:TwoPointFourFivePercentSeniorNotesDueAugustOneTwoThousandAndTwentyTwoMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-12-31 0000313927 2021-07-01 2021-09-30 0000313927 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000313927 us-gaap:CarryingReportedAmountFairValueDisclosureMember chd:TwoPointEightSevenFivePercentSeniorNotesDueOctoberOneTwoThousandAndTwentyTwoMember 2022-09-30 0000313927 us-gaap:IntersegmentEliminationMember 2021-01-01 2021-09-30 0000313927 us-gaap:CommonStockMember 2021-03-31 0000313927 us-gaap:ConstructionInProgressMember 2021-12-31 0000313927 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-12-31 0000313927 chd:ArmandProductsCompanyAndArmaKleenCompanyMember 2021-07-01 2021-09-30 0000313927 us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember 2021-12-31 0000313927 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-01-01 2021-09-30 0000313927 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000313927 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CommodityContractMember 2022-09-30 0000313927 us-gaap:SoftwareDevelopmentMember 2022-09-30 0000313927 chd:FlawlessTradenameMember 2022-01-01 2022-09-30 0000313927 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000313927 us-gaap:FairValueInputsLevel2Member chd:ThreePointNineFivePercentSeniorNotesDueAugustOneTwoThousandAndFortySevenMember 2022-09-30 0000313927 chd:ConsumerDomesticMember chd:ZicamAcquisitionMember 2022-09-30 0000313927 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:InterestRateSwapMember 2022-09-30 0000313927 chd:ConsumerDomesticMember chd:ZicamAcquisitionMember 2021-12-31 0000313927 chd:FivePointZeroZeroPercentSeniorNotesDueJuneFifteenTwoThousandFiftyTwoMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-12-31 0000313927 chd:ZicamAcquisitionMember 2020-01-01 2020-12-31 0000313927 chd:FivePointZeroZeroPercentageNotesDueJuneFifteenTwoThousandFiftyTwoMember 2021-01-01 2021-12-31 0000313927 us-gaap:TradeNamesMember 2022-09-30 0000313927 chd:TrojanTradeNameMember 2021-12-31 0000313927 us-gaap:ConstructionInProgressMember 2022-09-30 0000313927 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CommodityContractMember 2021-12-31 0000313927 chd:ZicamAcquisitionMember 2020-12-31 0000313927 us-gaap:AccumulatedTranslationAdjustmentMember 2022-09-30 0000313927 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0000313927 chd:InterestRateSwapLockMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0000313927 srt:MaximumMember chd:ZicamAcquisitionMember 2020-11-29 2020-12-01 0000313927 us-gaap:TreasuryStockMember 2020-12-31 0000313927 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0000313927 chd:ArmaKleenCompanyMember 2022-01-01 2022-09-30 0000313927 chd:ShareRepurchaseProgramMember 2021-01-01 2021-12-31 0000313927 chd:TwoPointsThreePercentSeniorNotesDueDecemberFifteenTwoThousandAndThirtyOneMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-12-31 0000313927 us-gaap:TradeNamesMember 2021-12-31 0000313927 chd:ThreePointNineFivePercentSeniorNotesDueAugustOneTwoThousandAndFortySevenMember 2021-01-01 2021-12-31 0000313927 chd:TwoPointsThreePercentSeniorNotesDueDecemberFifteenTwoThousandAndThirtyOneMember 2022-01-01 2022-09-30 0000313927 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-09-30 0000313927 us-gaap:FairValueInputsLevel2Member chd:ThreePointNineFivePercentSeniorNotesDueAugustOneTwoThousandAndFortySevenMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-09-30 0000313927 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000313927 2021-01-01 2021-12-31 0000313927 chd:TwoPointsThreePercentSeniorNotesDueDecemberFifteenTwoThousandAndThirtyOneMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0000313927 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000313927 chd:TwoPointEightSevenFivePercentSeniorNotesDueOctoberOneTwoThousandAndTwentyTwoMember 2021-01-01 2021-12-31 0000313927 us-gaap:RetainedEarningsMember 2020-12-31 0000313927 chd:ZicamAcquisitionMember 2020-12-01 0000313927 us-gaap:LandMember 2021-12-31 0000313927 chd:ZicamAcquisitionMember 2020-12-03 2020-12-31 0000313927 chd:ArmaKleenCompanyMember 2022-09-30 0000313927 us-gaap:CustomerRelationshipsMember 2022-09-30 0000313927 us-gaap:CommonStockMember 2022-03-31 0000313927 us-gaap:CommonStockMember 2021-06-30 0000313927 chd:ArmaKleenCompanyMember 2022-09-30 0000313927 us-gaap:FairValueInputsLevel2Member chd:TwoPointEightSevenFivePercentSeniorNotesDueOctoberOneTwoThousandAndTwentyTwoMember 2021-12-31 0000313927 chd:FivePointZeroZeroPercentSeniorNotesDueJuneFifteenTwoThousandFiftyTwoMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0000313927 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-09-30 0000313927 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ForeignExchangeContractMember 2022-09-30 0000313927 chd:TheraBreathAcquisitionMember 2021-01-01 2021-12-31 0000313927 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0000313927 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember chd:TermLoanDueInDecemberTwentyTwoTwoThousandAndTwentyFourMember 2022-09-30 0000313927 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-09-30 0000313927 us-gaap:EnergyRelatedDerivativeMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0000313927 srt:MinimumMember chd:TheraBreathAcquisitionMember 2021-12-23 2021-12-24 0000313927 chd:FivePointZeroZeroPercentSeniorNotesDueJuneFifteenTwoThousandFiftyTwoMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-09-30 0000313927 chd:TwoPointEightSevenFivePercentSeniorNotesDueOctoberOneTwoThousandAndTwentyTwoMember 2022-01-01 2022-09-30 0000313927 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:InterestRateSwapMember 2021-12-31 0000313927 us-gaap:OperatingSegmentsMember chd:ConsumerDomesticMember 2021-07-01 2021-09-30 0000313927 us-gaap:OperatingSegmentsMember chd:ConsumerDomesticMember chd:HouseholdProductsMember 2022-01-01 2022-09-30 0000313927 chd:FlawlessAcquisitionMember srt:MaximumMember 2022-01-01 2022-09-30 0000313927 us-gaap:OperatingSegmentsMember chd:ConsumerDomesticMember 2022-07-01 2022-09-30 0000313927 2021-03-31 0000313927 chd:ArmandProductsCompanyMember 2022-09-30 0000313927 us-gaap:CarryingReportedAmountFairValueDisclosureMember chd:TermLoanDueInDecemberTwentyTwoTwoThousandAndTwentyFourMember 2022-09-30 0000313927 us-gaap:OperatingSegmentsMember chd:ConsumerInternationalMember 2022-01-01 2022-09-30 0000313927 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0000313927 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-09-30 0000313927 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0000313927 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0000313927 2021-01-01 2021-09-30 0000313927 us-gaap:EquityContractMember us-gaap:NondesignatedMember 2021-12-31 0000313927 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-12-31 0000313927 chd:FivePointZeroZeroPercentageNotesDueJuneFifteenTwoThousandFiftyTwoMember 2022-10-31 0000313927 chd:ConsumerDomesticMember chd:FlawlessAcquisitionMember 2021-07-01 2021-09-30 0000313927 us-gaap:CommonStockMember 2021-12-31 0000313927 us-gaap:CustomerRelationshipsMember 2021-12-31 0000313927 chd:FlawlessAcquisitionMember 2022-01-01 2022-09-30 0000313927 us-gaap:OperatingSegmentsMember chd:HouseholdProductsMember chd:ConsumerDomesticMember 2021-07-01 2021-09-30 0000313927 us-gaap:CarryingReportedAmountFairValueDisclosureMember chd:ThreePointNineFivePercentSeniorNotesDueAugustOneTwoThousandAndFortySevenMember 2022-09-30 0000313927 chd:ZicamAcquisitionMember chd:ConsumerInternationalMember 2022-09-30 0000313927 chd:ArmandProductsCompanyAndArmaKleenCompanyMember 2022-07-01 2022-09-30 0000313927 us-gaap:FairValueInputsLevel2Member us-gaap:InterestRateSwapMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-12-31 0000313927 srt:MinimumMember chd:TheraBreathAcquisitionMember 2022-01-01 2022-09-30 0000313927 srt:MaximumMember 2019-05-01 2019-05-01 0000313927 us-gaap:MachineryAndEquipmentMember 2022-09-30 0000313927 chd:TheraBreathAcquisitionMember chd:ConsumerInternationalMember 2022-01-01 2022-09-30 0000313927 srt:MaximumMember chd:ZicamAcquisitionMember 2020-12-03 2020-12-31 0000313927 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000313927 2021-06-30 0000313927 srt:MinimumMember 2022-09-30 0000313927 chd:CommercialBankMember 2021-12-01 2021-12-31 0000313927 chd:FlawlessAcquisitionMember 2019-05-01 0000313927 us-gaap:TradeNamesMember 2021-12-31 0000313927 us-gaap:NondesignatedMember us-gaap:ForeignExchangeContractMember 2022-09-30 0000313927 chd:FivePointZeroZeroPercentSeniorNotesDueJuneFifteenTwoThousandFiftyTwoMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-12-31 0000313927 chd:TwoPointsThreePercentSeniorNotesDueDecemberFifteenTwoThousandAndThirtyOneMember 2021-01-01 2021-12-31 0000313927 chd:ArmandProductsCompanyAndArmaKleenCompanyMember 2022-01-01 2022-09-30 0000313927 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000313927 chd:ArmandProductsCompanyMember 2022-01-01 2022-09-30 0000313927 us-gaap:RevolvingCreditFacilityMember 2024-03-29 0000313927 us-gaap:IntersegmentEliminationMember 2022-01-01 2022-09-30 0000313927 chd:TwoPointsThreePercentSeniorNotesDueDecemberFifteenTwoThousandAndThirtyOneMember us-gaap:FairValueInputsLevel2Member 2022-09-30 0000313927 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000313927 us-gaap:CommonStockMember 2021-09-30 0000313927 chd:TwoPointsThreePercentSeniorNotesDueDecemberFifteenTwoThousandAndThirtyOneMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-09-30 0000313927 chd:ConsumerDomesticMember chd:FlawlessAcquisitionMember 2021-01-01 2021-09-30 0000313927 us-gaap:IntersegmentEliminationMember 2022-07-01 2022-09-30 0000313927 chd:ShareRepurchaseProgramMember 2021-12-01 2021-12-31 0000313927 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000313927 chd:ZicamAcquisitionMember chd:SpecialtyProductsDivisionMember 2022-09-30 0000313927 2022-09-30 0000313927 us-gaap:TreasuryStockMember 2022-06-30 0000313927 chd:TwoPointFourFivePercentSeniorNotesDueAugustOneTwoThousandAndTwentyTwoMember 2022-08-01 0000313927 us-gaap:FairValueInputsLevel2Member chd:TwoPointEightSevenFivePercentSeniorNotesDueOctoberOneTwoThousandAndTwentyTwoMember 2022-09-30 0000313927 chd:FivePointZeroZeroPercentageNotesDueJuneFifteenTwoThousandFiftyTwoMember 2022-10-31 2022-10-31 0000313927 chd:InterestRateSwapLockAgreementMember 2022-01-01 2022-09-30 0000313927 chd:ThreePointOneFivePercentSeniorNotesDueAugustOneTwoThousandAndTwentySevenMember 2021-12-31 0000313927 us-gaap:CommonStockMember 2022-06-30 0000313927 us-gaap:AccumulatedTranslationAdjustmentMember 2021-09-30 0000313927 chd:FivePointZeroZeroPercentSeniorNotesDueJuneFifteenTwoThousandFiftyTwoMember us-gaap:FairValueInputsLevel2Member 2022-09-30 0000313927 us-gaap:CorporateNonSegmentMember 2021-07-01 2021-09-30 0000313927 chd:FlawlessAcquisitionMember chd:UpdatedSalesForecastsMember 2021-01-01 2021-12-31 0000313927 chd:ZicamAcquisitionMember chd:SpecialtyProductsDivisionMember 2021-12-31 0000313927 chd:TwoPointEightSevenFivePercentSeniorNotesDueOctoberOneTwoThousandAndTwentyTwoMember 2022-10-31 0000313927 us-gaap:OperatingSegmentsMember chd:ConsumerInternationalMember 2021-01-01 2021-09-30 0000313927 us-gaap:SoftwareDevelopmentMember 2021-12-31 0000313927 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-09-30 0000313927 chd:FlawlessAcquisitionMember chd:ConsumerInternationalMember 2021-07-01 2021-09-30 0000313927 country:US 2021-01-01 2021-12-31 0000313927 chd:TheraBreathAcquisitionMember 2021-12-31 0000313927 us-gaap:FairValueInputsLevel2Member chd:ThreePointOneFivePercentSeniorNotesDueAugustOneTwoThousandAndTwentySevenMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-12-31 0000313927 us-gaap:RetainedEarningsMember 2022-09-30 0000313927 2021-10-28 0000313927 chd:FivePointZeroZeroPercentSeniorNotesDueJuneFifteenTwoThousandFiftyTwoMember 2021-12-31 0000313927 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000313927 us-gaap:OperatingSegmentsMember chd:HouseholdProductsMember chd:ConsumerDomesticMember 2022-07-01 2022-09-30 0000313927 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000313927 us-gaap:OperatingSegmentsMember chd:ConsumerDomesticMember 2021-01-01 2021-09-30 0000313927 us-gaap:RetainedEarningsMember 2021-03-31 0000313927 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-07-01 2021-09-30 0000313927 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0000313927 us-gaap:NonUsMember 2021-01-01 2021-12-31 0000313927 chd:FivePointZeroZeroPercentSeniorNotesDueJuneFifteenTwoThousandFiftyTwoMember 2022-09-30 0000313927 chd:FivePointZeroZeroPercentageNotesDueJuneFifteenTwoThousandFiftyTwoMember 2022-01-01 2022-09-30 0000313927 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000313927 chd:ShareRepurchaseProgramMember 2022-01-01 2022-09-30 0000313927 chd:FivePointZeroZeroPercentageNotesDueJuneFifteenTwoThousandFiftyTwoMember 2022-09-30 0000313927 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-09-30 0000313927 us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ForeignExchangeContractMember 2021-12-31 0000313927 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-01 2022-09-30 0000313927 srt:MinimumMember chd:TheraBreathAcquisitionMember 2021-12-24 2021-12-24 0000313927 us-gaap:CommonStockMember 2022-09-30 0000313927 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0000313927 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000313927 chd:ThreePointOneFivePercentSeniorNotesDueAugustOneTwoThousandAndTwentySevenMember 2021-01-01 2021-12-31 0000313927 chd:ThreePointNineFivePercentSeniorNotesDueAugustOneTwoThousandAndFortySevenMember 2022-09-30 0000313927 2022-01-01 2022-09-30 0000313927 us-gaap:OperatingSegmentsMember chd:SpecialtyProductsDivisionMember 2022-07-01 2022-09-30 0000313927 2020-12-31 0000313927 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000313927 chd:TheraBreathAcquisitionMember 2022-01-01 2022-09-30 0000313927 chd:TheraBreathAcquisitionMember 2021-12-10 0000313927 us-gaap:TreasuryStockMember 2021-06-30 0000313927 us-gaap:RetainedEarningsMember 2021-12-31 0000313927 us-gaap:IntersegmentEliminationMember 2021-07-01 2021-09-30 0000313927 2022-01-01 2022-03-31 0000313927 us-gaap:TreasuryStockMember 2022-04-01 2022-06-30 0000313927 2022-06-30 0000313927 srt:MaximumMember 2022-09-30 0000313927 us-gaap:OperatingSegmentsMember chd:ConsumerInternationalMember 2021-07-01 2021-09-30 0000313927 us-gaap:OperatingSegmentsMember chd:HouseholdProductsMember chd:ConsumerDomesticMember 2021-01-01 2021-09-30 0000313927 us-gaap:FairValueInputsLevel2Member chd:ThreePointOneFivePercentSeniorNotesDueAugustOneTwoThousandAndTwentySevenMember 2021-12-31 0000313927 us-gaap:OperatingSegmentsMember chd:SpecialtyProductsDivisionMember 2021-07-01 2021-09-30 0000313927 srt:MaximumMember chd:TheraBreathAcquisitionMember 2022-01-01 2022-09-30 0000313927 chd:FlawlessAcquisitionMember chd:UpdatedSalesForecastsMember 2020-01-01 2020-12-31 0000313927 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-12-31 0000313927 chd:ArmandProductsCompanyMember 2021-09-30 iso4217:USD xbrli:shares xbrli:pure utr:lb xbrli:shares chd:Tons iso4217:USD chd:Segment utr:gal

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(MARK ONE)

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarter ended September 30, 2022

OR

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 1-10585

CHURCH & DWIGHT CO., INC.

(Exact name of registrant as specified in its charter)

Delaware |  | 13-4996950
(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)

500 Charles Ewing Boulevard, Ewing, NJ 08628

(Address of principal executive offices)

Registrant’s telephone number, including area code: (609) 806-1200

Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, $1 par value |  | CHD | New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding twelve months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer |  | ☒ |  | Accelerated filer |  | ☐
Non-accelerated filer |  | ☐ |  | Smaller reporting company |  | ☐
Emerging growth company |  | ☐ |  |  |  |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of October 26, 2022, there were 243,868,347 shares of Common Stock outstanding.

TABLE OF CONTENTS

PART I

Item |  |  |  | Page
1. |  | Financial Statements |  | 3
2. |  | Management’s Discussion and Analysis of Financial Condition and Results of Operations |  | 23
3. |  | Quantitative and Qualitative Disclosures about Market Risk |  | 33
4. |  | Controls and Procedures |  | 33

PART II

1. |  | Legal Proceedings |  | 35
1A. |  | Risk Factors |  | 35
2. |  | Unregistered Sales of Equity Securities and Use of Proceeds |  | 36
6. |  | Exhibits |  | 37

2

PART I – FINANCIAL INFORMATION

ITEM 1: FINANCIAL STATEMENTS

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

(In millions, except per share data)

| Three Months Ended |  |  | Nine Months Ended |
| September 30, |  |  | September 30, |  |  | September 30, |  |  | September 30, |
| 2022 |  |  | 2021 |  |  | 2022 |  |  | 2021 |
Net Sales | $ | 1,317.3 |  |  | $ | 1,311.4 |  |  | $ | 3,939.6 |  |  | $ | 3,821.4 |
Cost of sales |  | 767.6 |  |  |  | 732.2 |  |  |  | 2,292.1 |  |  |  | 2,139.1 |
Gross Profit |  | 549.7 |  |  |  | 579.2 |  |  |  | 1,647.5 |  |  |  | 1,682.3 |
Marketing expenses |  | 140.7 |  |  |  | 160.9 |  |  |  | 345.5 |  |  |  | 376.6 |
Selling, general and administrative expenses |  | 155.1 |  |  |  | 116.9 |  |  |  | 505.8 |  |  |  | 403.0 |
Income from Operations |  | 253.9 |  |  |  | 301.4 |  |  |  | 796.2 |  |  |  | 902.7 |
Equity in earnings of affiliates |  | 3.7 |  |  |  | 2.0 |  |  |  | 10.0 |  |  |  | 7.4 |
Investment earnings, net |  | 1.5 |  |  |  | 0.0 |  |  |  | 1.8 |  |  |  | 0.1 |
Other income (expense), net |  | (0.9 | ) |  |  | (0.7 | ) |  |  | (1.2 | ) |  |  | (1.1 | )
Interest expense |  | (23.7 | ) |  |  | (13.4 | ) |  |  | (59.6 | ) |  |  | (41.5 | )
Income before Income Taxes |  | 234.5 |  |  |  | 289.3 |  |  |  | 747.2 |  |  |  | 867.6 |
Income taxes |  | 47.4 |  |  |  | 58.9 |  |  |  | 168.6 |  |  |  | 198.2 |
Net Income | $ | 187.1 |  |  | $ | 230.4 |  |  | $ | 578.6 |  |  | $ | 669.4 |
Weighted average shares outstanding - Basic |  | 242.8 |  |  |  | 245.3 |  |  |  | 242.7 |  |  |  | 245.2 |
Weighted average shares outstanding - Diluted |  | 246.0 |  |  |  | 249.8 |  |  |  | 246.4 |  |  |  | 249.9 |
Net income per share - Basic | $ | 0.77 |  |  | $ | 0.94 |  |  | $ | 2.38 |  |  | $ | 2.73 |
Net income per share - Diluted | $ | 0.76 |  |  | $ | 0.92 |  |  | $ | 2.35 |  |  | $ | 2.68 |
Cash dividends per share | $ | 0.26 |  |  | $ | 0.25 |  |  | $ | 0.79 |  |  | $ | 0.76 |

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)

(In millions)

| Three Months Ended |  |  | Nine Months Ended |
| September 30, |  |  | September 30, |  |  | September 30, |  |  | September 30, |
| 2022 |  |  | 2021 |  |  | 2022 |  |  | 2021 |
Net Income | $ | 187.1 |  |  | $ | 230.4 |  |  | $ | 578.6 |  |  | $ | 669.4 |
Other comprehensive income, net of tax: |  |  |  |  |  |  |  |  |  |  |
Foreign exchange translation adjustments |  | (13.3 | ) |  |  | (5.1 | ) |  |  | (27.8 | ) |  |  | (4.7 | )
Defined benefit plan adjustments gain (loss) | 0.0 |  |  | 0.0 |  |  |  | 1.9 |  |  |  | (0.7 | )
Income (loss) from derivative agreements |  | 14.3 |  |  |  | 10.0 |  |  |  | 48.0 |  |  |  | 22.1 |
Other comprehensive income (loss) |  | 1.0 |  |  |  | 4.9 |  |  |  | 22.1 |  |  |  | 16.7 |
Comprehensive income | $ | 188.1 |  |  | $ | 235.3 |  |  | $ | 600.7 |  |  | $ | 686.1 |

See Notes to Condensed Consolidated Financial Statements (Unaudited).

3

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In millions, except share and per share data)

| September 30, |  |  |  | December 31, |
| 2022 |  |  |  | 2021 |
Assets |  |  |  |  |  |
Current Assets |  |  |  |  |  |
Cash and cash equivalents | $ | 437.6 |  |  |  | $ | 240.6 |
Accounts receivable, less allowances of $4.0 and $5.5 |  | 391.3 |  |  |  |  | 405.5 |
Inventories |  | 675.3 |  |  |  |  | 535.4 |
Other current assets |  | 60.2 |  |  |  |  | 51.9 |
Total Current Assets |  | 1,564.4 |  |  |  |  | 1,233.4 |
Property, Plant and Equipment, Net |  | 716.3 |  |  |  |  | 652.7 |
Equity Investment in Affiliates |  | 11.9 |  |  |  |  | 9.1 |
Trade Names and Other Intangibles, Net |  | 3,404.1 |  |  |  |  | 3,494.3 |
Goodwill |  | 2,270.7 |  |  |  |  | 2,274.5 |
Other Assets |  | 320.4 |  |  |  |  | 332.5 |
Total Assets | $ | 8,287.8 |  |  |  | $ | 7,996.5 |
Liabilities and Stockholders' Equity |  |  |  |  |  |
Current Liabilities |  |  |  |  |  |
Short-term borrowings | $ | 3.3 |  |  |  | $ | 252.8 |
Current portion of long-term debt |  | 400.0 |  |  |  |  | 699.4 |
Accounts payable and accrued expenses |  | 1,032.0 |  |  |  |  | 1,119.7 |
Income taxes payable |  | 15.3 |  |  |  |  | 3.3 |
Total Current Liabilities |  | 1,450.6 |  |  |  |  | 2,075.2 |
Long-term Debt |  | 2,104.4 |  |  |  |  | 1,610.7 |
Deferred Income Taxes |  | 738.9 |  |  |  |  | 745.1 |
Deferred and Other Long-term Liabilities |  | 272.1 |  |  |  |  | 298.3 |
Business Acquisition Liabilities |  | 34.0 |  |  |  |  | 34.0 |
Total Liabilities |  | 4,600.0 |  |  |  |  | 4,763.3 |
Commitments and Contingencies |  |  |  |  |  |
Stockholders' Equity |  |  |  |  |  |
Preferred Stock, $1.00 par value, Authorized 2,500,000 shares; none issued |  | 0.0 |  |  |  |  | 0.0 |
Common Stock, $1.00 par value, Authorized 600,000,000 shares and 292,855,100 shares issued as of September 30, 2022 and December 31, 2021 |  | 292.8 |  |  |  |  | 292.8 |
Additional paid-in capital |  | 355.9 |  |  |  |  | 310.3 |
Retained earnings |  | 5,753.4 |  |  |  |  | 5,366.0 |
Accumulated other comprehensive loss |  | (46.1 | ) |  |  |  | (68.2 | )
Common stock in treasury, at cost: 49,896,366 shares as of September 30, 2022 and 50,309,124 shares as of December 31, 2021 |  | (2,668.2 | ) |  |  |  | (2,667.7 | )
Total Stockholders' Equity |  | 3,687.8 |  |  |  |  | 3,233.2 |
Total Liabilities and Stockholders' Equity | $ | 8,287.8 |  |  |  | $ | 7,996.5 |

See Notes to Condensed Consolidated Financial Statements (Unaudited).

4

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW

(Unaudited)

(In millions)

| Nine Months Ended |
| September 30, |  |  | September 30, |
| 2022 |  |  | 2021 |
Cash Flow From Operating Activities |  |  |  |  |
Net Income | $ | 578.6 |  |  | $ | 669.4 |
Adjustments to reconcile net income to net cash provided by operating activities: |  |  |  |  |
Depreciation expense |  | 50.1 |  |  |  | 51.3 |
Amortization expense |  | 110.5 |  |  |  | 113.6 |
Change in fair value of business acquisition liabilities |  | 0.0 |  |  |  | (98.0 | )
Deferred income taxes |  | (12.7 | ) |  |  | 32.8 |
Equity in net earnings of affiliates |  | (10.0 | ) |  |  | (7.4 | )
Distributions from unconsolidated affiliates |  | 7.2 |  |  |  | 7.5 |
Non-cash compensation expense |  | 22.0 |  |  |  | 20.3 |
Other |  | (1.5 | ) |  |  | 5.8 |
Change in assets and liabilities: |  |  |  |  |
Accounts receivable |  | (1.7 | ) |  |  | (12.0 | )
Inventories |  | (152.7 | ) |  |  | (59.9 | )
Other current assets |  | 4.7 |  |  |  | 6.1 |
Accounts payable and accrued expenses |  | (56.0 | ) |  |  | (50.8 | )
Income taxes payable |  | 16.5 |  |  |  | (10.3 | )
Other operating assets and liabilities, net |  | (20.9 | ) |  |  | (14.8 | )
Net Cash Provided By Operating Activities |  | 534.1 |  |  |  | 653.6 |
Cash Flow From Investing Activities |  |  |  |  |
Additions to property, plant and equipment |  | (98.1 | ) |  |  | (64.1 | )
Other |  | (2.6 | ) |  |  | (5.6 | )
Net Cash Used In Investing Activities |  | (100.7 | ) |  |  | (69.7 | )
Cash Flow From Financing Activities |  |  |  |  |
Long-term debt borrowings |  | 499.8 |  |  |  | 0.0 |
Long-term debt (repayments) |  | (300.0 | ) |  |  | (300.0 | )
Short-term debt (repayments), net of borrowings |  | (249.5 | ) |  |  | (71.6 | )
Proceeds from stock options exercised |  | 22.4 |  |  |  | 26.9 |
Payment of cash dividends |  | (191.2 | ) |  |  | (185.8 | )
Purchase of treasury stock |  | 0.0 |  |  |  | (54.9 | )
Deferred financing and other |  | (7.5 | ) |  |  | 0.0 |
Net Cash Provided By (Used In) Financing Activities |  | (226.0 | ) |  |  | (585.4 | )
Effect of exchange rate changes on cash and cash equivalents |  | (10.4 | ) |  |  | (1.6 | )
Net Change In Cash and Cash Equivalents |  | 197.0 |  |  |  | (3.1 | )
Cash and Cash Equivalents at Beginning of Period |  | 240.6 |  |  |  | 183.1 |
Cash and Cash Equivalents at End of Period | $ | 437.6 |  |  | $ | 180.0 |

See Notes to Condensed Consolidated Financial Statements (Unaudited).

5

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW-CONTINUED

(Unaudited)

(In millions)

| Nine Months Ended |
| September 30, |  |  | September 30, |
| 2022 |  |  | 2021 |
Cash paid during the period for: |  |  |  |  |
Interest (net of amounts capitalized) | $ | 54.0 |  |  | $ | 45.4 |
Income taxes | $ | 165.5 |  |  | $ | 175.7 |
Supplemental disclosure of non-cash investing activities: |  |  |  |  |
Property, plant and equipment expenditures included in Accounts Payable | $ | 34.4 |  |  | $ | 11.2 |

See Notes to Condensed Consolidated Financial Statements (Unaudited).

6

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

(In millions)

| Number of Shares |  |  | Amounts |
| Common Stock |  |  | Treasury Stock |  |  | Common Stock |  |  | Additional Paid-In Capital |  |  | Retained Earnings |  |  | Accumulated Other Comprehensive Income (Loss) |  |  | Treasury Stock |  |  | Total Stockholders' Equity |
December 31, 2020 |  | 292.8 |  |  |  | (47.4 | ) |  | $ | 292.8 |  |  | $ | 274.4 |  |  | $ | 4,786.0 |  |  | $ | (77.6 | ) |  | $ | (2,255.2 | ) |  | $ | 3,020.4 |
Net income |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 220.7 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 220.7 |
Other comprehensive income (loss) |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 23.0 |  |  |  | 0.0 |  |  |  | 23.0 |
Cash dividends |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | (61.9 | ) |  |  | 0.0 |  |  |  | 0.0 |  |  |  | (61.9 | )
Stock purchases |  | 0.0 |  |  |  | (0.4 | ) |  |  | 0.0 |  |  |  | 30.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | (30.0 | ) |  |  | 0.0 |
Stock based compensation expense and stock option plan transactions |  | 0.0 |  |  |  | 0.1 |  |  |  | 0.0 |  |  |  | 1.8 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 7.2 |  |  |  | 9.0 |
March 31, 2021 |  | 292.8 |  |  |  | (47.7 | ) |  | $ | 292.8 |  |  | $ | 306.2 |  |  | $ | 4,944.8 |  |  | $ | (54.6 | ) |  | $ | (2,278.0 | ) |  | $ | 3,211.2 |
Net income |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 218.3 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 218.3 |
Other comprehensive income (loss) |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | (11.2 | ) |  |  | 0.0 |  |  |  | (11.2 | )
Cash dividends |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | (61.9 | ) |  |  | 0.0 |  |  |  | 0.0 |  |  |  | (61.9 | )
Stock based compensation expense and stock option plan transactions |  | 0.0 |  |  |  | 0.2 |  |  |  | 0.0 |  |  |  | 14.3 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 6.5 |  |  |  | 20.8 |
June 30, 2021 |  | 292.8 |  |  |  | (47.5 | ) |  | $ | 292.8 |  |  | $ | 320.5 |  |  | $ | 5,101.2 |  |  | $ | (65.8 | ) |  | $ | (2,271.5 | ) |  | $ | 3,377.2 |
Net income |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 230.4 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 230.4 |
Other comprehensive income (loss) |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 4.9 |  |  |  | 0.0 |  |  |  | 4.9 |
Cash dividends |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | (62.0 | ) |  |  | 0.0 |  |  |  | 0.0 |  |  |  | (62.0 | )
Stock purchases |  | 0.0 |  |  |  | (0.7 | ) |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | (54.9 | ) |  |  | (54.9 | )
Stock based compensation expense and stock option plan transactions |  | 0.0 |  |  |  | 0.3 |  |  |  | 0.0 |  |  |  | 7.4 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 10.6 |  |  |  | 18.0 |
September 30, 2021 |  | 292.8 |  |  |  | (47.9 | ) |  | $ | 292.8 |  |  | $ | 327.9 |  |  | $ | 5,269.6 |  |  | $ | (60.9 | ) |  | $ | (2,315.8 | ) |  | $ | 3,513.6 |

See Notes to Condensed Consolidated Financial Statements (Unaudited).

7

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY-CONTINUED

(Unaudited)

(In millions)

| Number of Shares |  |  | Amounts |
| Common Stock |  |  | Treasury Stock |  |  | Common Stock |  |  | Additional Paid-In Capital |  |  | Retained Earnings |  |  | Accumulated Other Comprehensive Income (Loss) |  |  | Treasury Stock |  |  | Total Stockholders' Equity |
December 31, 2021 |  | 292.8 |  |  |  | (50.3 | ) |  | $ | 292.8 |  |  | $ | 310.3 |  |  | $ | 5,366.0 |  |  | $ | (68.2 | ) |  | $ | (2,667.7 | ) |  | $ | 3,233.2 |
Net income |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 204.4 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 204.4 |
Other comprehensive income (loss) |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 15.0 |  |  |  | 0.0 |  |  |  | 15.0 |
Cash dividends |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | (63.7 | ) |  |  | 0.0 |  |  |  | 0.0 |  |  |  | (63.7 | )
Stock purchases |  | 0.0 |  |  |  | (0.2 | ) |  |  | 0.0 |  |  |  | 20.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | (20.0 | ) |  |  | 0.0 |
Stock based compensation expense and stock option plan transactions |  | 0.0 |  |  |  | 0.3 |  |  |  | 0.0 |  |  |  | 3.9 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 10.1 |  |  |  | 14.0 |
March 31, 2022 |  | 292.8 |  |  |  | (50.2 | ) |  | $ | 292.8 |  |  | $ | 334.2 |  |  | $ | 5,506.7 |  |  | $ | (53.2 | ) |  | $ | (2,677.6 | ) |  | $ | 3,402.9 |
Net income |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 187.1 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 187.1 |
Other comprehensive income (loss) |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 6.1 |  |  |  | 0.0 |  |  |  | 6.1 |
Cash dividends |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | (63.7 | ) |  |  | 0.0 |  |  |  | 0.0 |  |  |  | (63.7 | )
Stock based compensation expense and stock option plan transactions |  | 0.0 |  |  |  | 0.2 |  |  |  | 0.0 |  |  |  | 15.9 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 6.1 |  |  |  | 22.0 |
June 30, 2022 |  | 292.8 |  |  |  | (50.0 | ) |  | $ | 292.8 |  |  | $ | 350.1 |  |  | $ | 5,630.1 |  |  | $ | (47.1 | ) |  | $ | (2,671.5 | ) |  | $ | 3,554.4 |
Net income |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 187.1 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 187.1 |
Other comprehensive income (loss) |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 1.0 |  |  |  | 0.0 |  |  |  | 1.0 |
Cash dividends |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | (63.8 | ) |  |  | 0.0 |  |  |  | 0.0 |  |  |  | (63.8 | )
Stock based compensation expense and stock option plan transactions |  | 0.0 |  |  |  | 0.1 |  |  |  | 0.0 |  |  |  | 5.8 |  |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 3.3 |  |  |  | 9.1 |
September 30, 2022 |  | 292.8 |  |  |  | (49.9 | ) |  | $ | 292.8 |  |  | $ | 355.9 |  |  | $ | 5,753.4 |  |  | $ | (46.1 | ) |  | $ | (2,668.2 | ) |  | $ | 3,687.8 |

See Notes to Condensed Consolidated Financial Statements (Unaudited).

8

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(In millions, except per share data)

1.
Basis of Presentation

These condensed consolidated financial statements have been prepared by Church & Dwight Co., Inc. (the “Company”). In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position and results of operations and cash flows for all periods presented have been made. Results of operations for interim periods may not be representative of results to be expected for the full year.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States have been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 (the “Form 10-K”).

The Company incurred research and development expenses in the third quarter of 2022 and 2021 of $29.2 and $27.7, respectively. The Company incurred research and development expenses in the first nine months of 2022 and 2021 of $80.9 and $77.2, respectively. These expenses are included in selling, general and administrative (“SG&A”) expenses.

2.
New Accounting Pronouncements

Recently Adopted Accounting Pronouncements

In March 2020, the FASB issued new accounting guidance intended to provide temporary optional expedients and exceptions to the U.S. GAAP guidance on contract modifications and hedge accounting to ease the financial reporting burdens related to the expected market transition from the London Interbank Offered Rate (“LIBOR”) and other interbank offered rates to alternative reference rates. This guidance was effective beginning on March 12, 2020, and the Company may apply the amendments prospectively to contract modifications made or relationships entered into or evaluated through December 31, 2022. The adoption of this guidance did not have an impact on the Company’s consolidated financial position, results of operations or cash flows in the current period. The Company will continue to evaluate the impacts of this guidance on future contracts through December 31, 2022.

Recent Accounting Pronouncements Not Yet Adopted

In September 2022, the FASB issued new accounting guidance intended to add certain qualitative and quantitative disclosure requirements for a buyer in a supplier finance program. The amendments require a buyer that uses supplier finance programs to make annual disclosures about the program’s key terms, the balance sheet presentation of related amounts, the confirmed amount outstanding at the end of the period, and associated rollforward information. Only the amount outstanding at the end of the period must be disclosed in interim periods. The amendments are effective for all entities for fiscal years beginning after December 15, 2022 on a retrospective basis, including interim periods within those fiscal years, except for the requirement to disclose rollforward information, which is effective prospectively for fiscal years beginning after December 15, 2023. The Company is currently evaluating the impact of adoption, which is expected to result in additional disclosures in 2023.

There have been no other accounting pronouncements issued but not yet adopted by the Company which are expected to have a material impact on the Company’s consolidated financial position, results of operations or cash flows.

3.
Inventories

Inventories consist of the following:

|  | September 30, |  |  | December 31, |
|  | 2022 |  |  | 2021 |
Raw materials and supplies |  | $ | 145.1 |  |  | $ | 116.2 |
Work in process |  |  | 51.6 |  |  |  | 40.0 |
Finished goods |  |  | 478.6 |  |  |  | 379.2 |
Total |  | $ | 675.3 |  |  | $ | 535.4 |

9

4.
Property, Plant and Equipment, Net (“PP&E”)

PP&E consists of the following:

|  | September 30, |  |  | December 31, |
|  | 2022 |  |  | 2021 |
Land |  | $ | 28.1 |  |  | $ | 28.3 |
Buildings and improvements |  |  | 292.2 |  |  |  | 290.8 |
Machinery and equipment |  |  | 851.9 |  |  |  | 828.9 |
Software |  |  | 110.6 |  |  |  | 107.8 |
Office equipment and other assets |  |  | 93.8 |  |  |  | 92.7 |
Construction in progress |  |  | 175.7 |  |  |  | 104.3 |
Gross PP&E |  |  | 1,552.3 |  |  |  | 1,452.8 |
Less accumulated depreciation and amortization |  |  | 836.0 |  |  |  | 800.1 |
Net PP&E |  | $ | 716.3 |  |  | $ | 652.7 |

| Three Months Ended |  |  | Nine Months Ended |
| September 30, |  |  | September 30, |  |  | September 30, |  |  | September 30, |
| 2022 |  |  | 2021 |  |  | 2022 |  |  | 2021 |
Depreciation expense on PP&E | $ | 16.7 |  |  | $ | 17.2 |  |  | $ | 50.1 |  |  | $ | 51.3 |

5.
Earnings Per Share (“EPS”)

Basic EPS is calculated based on income available to holders of the Company’s common stock (“Common Stock”) and the weighted average number of shares outstanding during the reported period. Diluted EPS includes additional dilution from potential Common Stock issuable pursuant to the exercise of outstanding stock options.

The following table sets forth a reconciliation of the weighted average number of shares of Common Stock outstanding to the weighted average number of shares outstanding on a diluted basis:

| Three Months Ended |  |  | Nine Months Ended |
| September 30, |  |  | September 30, |  |  | September 30, |  |  | September 30, |
| 2022 |  |  | 2021 |  |  | 2022 |  |  | 2021 |
Weighted average common shares outstanding - basic |  | 242.8 |  |  |  | 245.3 |  |  |  | 242.7 |  |  |  | 245.2 |
Dilutive effect of stock options |  | 3.2 |  |  |  | 4.5 |  |  |  | 3.7 |  |  |  | 4.7 |
Weighted average common shares outstanding - diluted |  | 246.0 |  |  |  | 249.8 |  |  |  | 246.4 |  |  |  | 249.9 |
Antidilutive stock options outstanding |  | 3.0 |  |  |  | 1.6 |  |  |  | 3.0 |  |  |  | 1.6 |

6.
Stock Based Compensation Plans

The following table provides a summary of option activity:

|  |  |  |  |  |  | Weighted |  |  |  |
|  |  |  |  |  |  | Average |  |  |  |
|  |  |  | Weighted |  |  | Remaining |  |  |  |
|  |  |  | Average |  |  | Contractual |  |  | Aggregate |
|  |  |  | Exercise |  |  | Term |  |  | Intrinsic |
| Options |  |  | Price |  |  | (in Years) |  |  | Value |
Outstanding at December 31, 2021 |  | 11.3 |  |  | $ | 58.83 |  |  |  |  |  |  |
Granted |  | 1.5 |  |  |  | 85.21 |  |  |  |  |  |  |
Exercised |  | (0.6 | ) |  |  | 40.81 |  |  |  |  |  |  |
Cancelled |  | (0.3 | ) |  |  | 78.76 |  |  |  |  |  |  |
Outstanding at September 30, 2022 |  | 11.9 |  |  | $ | 62.53 |  |  |  | 5.9 |  |  | $ | 159.0 |
Exercisable at September 30, 2022 |  | 7.3 |  |  | $ | 50.77 |  |  |  | 4.2 |  |  | $ | 159.0 |

10

The following table provides information regarding the intrinsic value of stock options exercised and stock compensation expense related to stock option awards:

| Three Months Ended |  |  | Nine Months Ended |
| September 30, |  |  | September 30, |  |  | September 30, |  |  | September 30, |
| 2022 |  |  | 2021 |  |  | 2022 |  |  | 2021 |
Intrinsic Value of Stock Options Exercised | $ | 3.3 |  |  | $ | 12.0 |  |  | $ | 29.6 |  |  | $ | 30.8 |
Stock Compensation Expense Related to Stock Option Awards | $ | 4.1 |  |  | $ | 3.4 |  |  | $ | 21.6 |  |  | $ | 19.9 |
Issued Stock Options |  | 0.0 |  |  |  | 0.0 |  |  |  | 1.5 |  |  |  | 1.5 |
Weighted Average Fair Value of Stock Options issued (per share) | $ | 0.0 |  |  | $ | 0.0 |  |  | $ | 21.48 |  |  | $ | 17.33 |
Fair Value of Stock Options Issued | $ | 0.0 |  |  | $ | 0.0 |  |  | $ | 32.7 |  |  | $ | 26.1 |

The following table provides a summary of the assumptions used in the valuation of issued stock options:

| Three Months Ended |  | Nine Months Ended |
| September 30, |  | September 30, |  | September 30, |  |  | September 30, |
| 2022 |  | 2021 |  | 2022 |  |  | 2021 |
Risk-free interest rate | - |  | - |  |  | 2.9 | % |  |  | 1.3 | %
Expected life in years | - |  | - |  |  | 7.1 |  |  |  | 7.2 |
Expected volatility | - |  | - |  |  | 21.7 | % |  |  | 20.7 | %
Dividend yield | - |  | - |  |  | 1.2 | % |  |  | 1.2 | %

7.
Share Repurchases

On October 28, 2021, the Board authorized a new share repurchase program, under which the Company may repurchase up to $1,000.0 in shares of Common Stock (the “2021 Share Repurchase Program”). The 2021 Share Repurchase Program does not have an expiration and replaced the 2017 Share Repurchase Program. All remaining dollars authorized for repurchase under the 2017 Share Repurchase Plan have been cancelled. The 2021 Share Repurchase Program did not modify the Company’s evergreen share repurchase program, authorized by the Board on January 29, 2014, under which the Company may repurchase, from time to time, Common Stock to reduce or eliminate dilution associated with issuances of Common Stock under its incentive plans.

In December 2021, the Company executed open market purchases of 1.8 million shares for $170.3, inclusive of fees, of which $100.0 was purchased under the evergreen share repurchase program and $70.3 was purchased under the 2021 Share Repurchase Program. In December 2021, the Company also entered into an accelerated share repurchase contract ("ASR") with a commercial bank to purchase Common Stock. The Company paid $200.0 to the bank, inclusive of fees, and received an initial delivery of shares equal to $180.0, or 1.8 million shares. The Company used cash on hand and short-term borrowings to fund the initial purchase price. Upon the completion of the ASR, which ended in February 2022, the bank delivered an additional 0.2 million shares to the Company. The final shares delivered to the Company were determined by the average price per share paid by the bank during the purchase period. All 2.0 million shares were purchased under the 2021 Share Repurchase Program.

As a result of the Company’s recent stock repurchases, there remains $729.7 of share repurchase availability under the 2021 Share Repurchase Program as of September 30, 2022.

11

8.
Fair Value Measurements

The following table provides the carrying amounts and estimated fair values of the Company’s financial instruments at September 30, 2022 and December 31, 2021:

|  |  | September 30, 2022 |  |  | December 31, 2021 |
| Input |  | Carrying |  |  | Fair |  |  | Carrying |  |  | Fair |
| Level |  | Amount |  |  | Value |  |  | Amount |  |  | Value |
Financial Assets: |  |  |  |  |  |  |  |  |  |  |  |  |
Cash equivalents | Level 1 |  | $ | 192.0 |  |  | $ | 192.0 |  |  | $ | 17.1 |  |  | $ | 17.1 |
Financial Liabilities: |  |  |  |  |  |  |  |  |  |  |  |  |
Short-term borrowings | Level 2 |  |  | 3.3 |  |  |  | 3.3 |  |  |  | 252.8 |  |  |  | 252.8 |
2.45% Senior notes due August 1, 2022 | Level 2 |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 300.0 |  |  |  | 302.9 |
2.875% Senior notes due October 1, 2022 | Level 2 |  |  | 400.0 |  |  |  | 400.0 |  |  |  | 399.9 |  |  |  | 406.4 |
Term loan due December 22, 2024 | Level 2 |  |  | 400.0 |  |  |  | 400.0 |  |  |  | 400.0 |  |  |  | 400.0 |
3.15% Senior notes due August 1, 2027 | Level 2 |  |  | 424.8 |  |  |  | 387.7 |  |  |  | 424.7 |  |  |  | 450.1 |
2.3% Senior notes due December 15, 2031 | Level 2 |  |  | 399.2 |  |  |  | 313.2 |  |  |  | 399.2 |  |  |  | 403.5 |
3.95% Senior notes due August 1, 2047 | Level 2 |  |  | 397.6 |  |  |  | 313.5 |  |  |  | 397.5 |  |  |  | 471.6 |
5.00% Senior notes due June 15, 2052 | Level 2 |  |  | 499.8 |  |  |  | 458.3 |  |  | 0.0 |  |  | 0.0 |
Interest Rate Lock Agreement (asset) liability | Level 2 |  |  | (12.5 | ) |  |  | (12.5 | ) |  |  | 41.6 |  |  |  | 41.6 |
Business Acquisition Liabilities | Level 3 |  |  | 34.0 |  |  |  | 34.0 |  |  |  | 34.0 |  |  |  | 34.0 |

The Company recognizes transfers between input levels as of the actual date of the event. There were no transfers between input levels during the nine months ended September 30, 2022.

Refer to Note 2 in the Form 10-K for a description of the methods and assumptions used to estimate the fair value of each class of financial instruments reflected in the condensed consolidated balance sheets.

The business acquisition liabilities represent the estimated fair value of additional future contingent consideration payable for acquisitions of businesses that included contingent consideration clauses. The fair value of business acquisition liabilities is evaluated on an ongoing basis and is based on management estimates and entity-specific assumptions which are considered Level 3 inputs. As of both September 30, 2022 and December 31, 2021, the Company had a business acquisition liability of $20.0 in connection with the Zicam Acquisition and a $14.0 business acquisition liability in connection with the TheraBreath Acquisition (b oth of which are defined in Note 10). Any amount that may be due for the Zicam business acquisition liability is payable five years from the closing date. Any amount that may be due for the TheraBreath business acquisition liability is payable in installments between two and four years from the closing.

The interest rate lock agreements outstanding as of December 31, 2021 were used to hedge the risk of changes in the interest payments associated with the 5.0% Senior Notes due June 15, 2052. These agreements were settled in the second quarter of 2022 for a loss of $4.2, which will be amortized into interest expense over ten years. The Company has entered into additional interest rate lock agreements in the third quarter of 2022 which are used to hedge the risk of changes in the interest payments associated with the anticipated issuance of debt in the fourth quarter of 2022.

The carrying amounts of Accounts Receivable, and Accounts Payable and Accrued Expenses, approximated estimated fair values as of September 30, 2022 and December 31, 2021.

12

9.
Derivative Instruments and Risk Management

Changes in interest rates, foreign exchange rates, the price of the Common Stock and commodity prices expose the Company to market risk. The Company manages these risks by the use of derivative instruments, such as cash flow and fair value hedges, diesel and commodity hedge contracts, equity derivatives and foreign exchange forward contracts. The Company does not use derivatives for trading or speculative purposes. Refer to Note 3 in the Form 10-K for a discussion of each of the Company’s derivative instruments in effect as of December 31, 2021.

The notional amount of a derivative instrument is the nominal or face amount used to calculate payments made on that instrument. Notional amounts are presented in the following table:

|  | Notional |  |  | Notional |
|  | Amount |  |  | Amount |
|  | September 30, 2022 |  |  | December 31, 2021 |
Derivatives designated as hedging instruments |  |  |  |  |  |
Foreign exchange contracts |  | $ | 219.9 |  |  | $ | 216.3 |
Interest rate lock agreements |  | $ | 500.0 |  |  | $ | 300.0 |
Diesel fuel contracts |  | 3.9 gallons |  |  | 0.0 gallons |
Commodities contracts |  | 8.6 pounds |  |  | 72.1 pounds |
Derivatives not designated as hedging instruments |  |  |  |  |  |
Foreign exchange contracts |  | $ | 5.9 |  |  | $ | 5.9 |
Equity derivatives |  | $ | 23.8 |  |  | $ | 28.9 |

Excluding the interest rate lock agreements, the fair values and amount of gain (loss) recognized in income and Other Comprehensive Income (“OCI”) associated with the derivative instruments disclosed above did not have a material impact on the Company’s condensed consolidated financial statements during the three and nine months ended September 30, 2022. The interest rate lock agreements outstanding at December 31, 2021 were settled in the second quarter of 2022 for a loss of $4.2, which will be amortized into interest expense over ten years. The Company has entered into additional interest rate lock agreements in the third quarter of 2022 which are used to hedge the risk of changes in the interest payments associated with the anticipated issuance of debt in the fourth quarter of 2022.

10.
Acquisitions

On December 24, 2021, the Company acquired all of the outstanding equity of Dr. Harold Katz, LLC and HK-IP International, Inc., the owners of the THERABREATH® brand of oral care products business (the “TheraBreath Acquisition”). The Company paid $556.0, net of cash acquired, at closing and deferred an additional cash payment of $14.0 related to certain indemnity obligations provided by the seller. The deferred amount is recorded in Business Acquisition Liabilities on the consolidated balance sheet and the additional amount, to the extent not used in satisfaction of such indemnity obligations, is payable in installments between two and four years from the closing. THERABREATH’s annual net sales for the year ended December 31, 2021 were approximately $100.0. The acquisition was financed by the proceeds from a $400.0 three-year term loan and the Company’s underwritten public offering of $400.0 aggregate principal 2.30% Senior Notes due on December 15, 2031 completed on December 10, 2021. The THERABREATH business is managed in the Consumer Domestic and Consumer International segments.

The fair values of the net assets at acquisition are set forth as follows:

Accounts receivable | $ | 11.3 |
Inventory |  | 12.9 |
Trade name (indefinite lived) |  | 487.0 |
Other intangible assets |  | 30.1 |
Goodwill |  | 39.9 |
Accounts payable and accrued expenses |  | (11.2 | )
Business acquisition liabilities - long-term |  | (14.0 | )
Cash purchase price (net of cash acquired) | $ | 556.0 |

The trade names and other intangible assets were valued using a discounted cash flow model. The life of the amortizable intangible assets recognized from the TheraBreath Acquisition have a useful life which ranges from 10 - 20 years. The goodwill is a result of expected synergies from combined operations of the acquired business and the Company. Pro forma results are not presented because the impact of the acquisition was not material to the Company’s consolidated financial results. The goodwill and other intangible assets associated with the TheraBreath Acquisition are deductible for U.S. tax purposes.

13

On December 1, 2020, the Company acquired all of the outstanding equity of Consumer Health Holdco LLC, the owner of the ZICAM® brand and cold remedy products business (the “Zicam Acquisition”). The Company paid $512.7, net of cash acquired, at closing and deferred an additional cash payment of $20.0 related to certain indemnifications provided by the seller. The deferred amount is recorded in Business Acquisition Liabilities on the consolidated balance sheet and any amount that may be due for the business acquisition liability is payable five years from the closing. Zicam’s annual net sales for the year ended December 31, 2020 were approximately $107.0. The acquisition was financed by the Company with a combination of cash on hand and short-term borrowings. The ZICAM business is managed in the Consumer Domestic segment.

The fair values of the net assets at acquisition are set forth as follows:

Inventory and other working capital | $ | 40.2 |
Property, plant and equipment |  | 0.5 |
Trade name |  | 367.8 |
Other intangible assets |  | 93.8 |
Goodwill |  | 152.2 |
Current liabilities |  | (13.1 | )
Deferred income taxes |  | (108.0 | )
Long-term liabilities |  | (20.7 | )
Cash purchase price (net of cash acquired) | $ | 512.7 |

The trade names and other intangible assets were valued using a discounted cash flow model. All of the intangible assets recognized from the Zicam Acquisition have a useful life which ranges from 10 - 20 years. The goodwill is a result of expected synergies from combined operations of the acquired business and the Company. Pro forma results are not presented because the impact of the acquisition was not material to the Company’s consolidated financial results. The goodwill and other intangible assets associated with the Zicam Acquisition are not deductible for U.S. tax purposes.

11.
Goodwill and Other Intangibles, Net

The following table provides information related to the carrying value of all intangible assets, other than goodwill:

| September 30, 2022 |  |  | December 31, 2021 |
| Gross |  |  |  |  |  |  |  |  | Gross |  |  |  |  |  |  |
| Carrying |  |  | Accumulated |  |  |  |  |  | Carrying |  |  | Accumulated |  |  |  |
| Amount |  |  | Amortization |  |  | Net |  |  | Amount |  |  | Amortization |  |  | Net |
Amortizable intangible assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Trade Names | $ | 1,384.7 |  |  | $ | (384.5 | ) |  | $ | 1,000.2 |  |  | $ | 1,386.7 |  |  | $ | (336.2 | ) |  | $ | 1,050.5 |
Customer Relationships |  | 664.0 |  |  |  | (349.3 | ) |  |  | 314.7 |  |  |  | 664.0 |  |  |  | (322.4 | ) |  |  | 341.6 |
Patents/Formulas |  | 239.1 |  |  |  | (110.6 | ) |  |  | 128.5 |  |  |  | 239.1 |  |  |  | (99.4 | ) |  |  | 139.7 |
Total | $ | 2,287.8 |  |  | $ | (844.4 | ) |  | $ | 1,443.4 |  |  | $ | 2,289.8 |  |  | $ | (758.0 | ) |  | $ | 1,531.8 |

Indefinite Lived Intangible Assets - Gross Carrying Amount

| September 30, |  |  | December 31, |  |  |  |  |  |  |  |  |
| 2022 |  |  | 2021 |  |  |  |  |  |  |  |  |
Trade Names | $ | 1,960.7 |  |  | $ | 1,962.5 |  |  |  |  |  |  |  |  |

Intangible amortization expense was $29.3 and $29.9 for the third quarter of 2022 and 2021, respectively. Intangible amortization expense amounted to $88.1 and $90.9 for the first nine months of 2022 and 2021, respectively. The Company estimates that intangible amortization expense will be approximately $117.0 in 2022 and approximately $115.0 to $107.0 annually over the next five years.

The Company’s indefinite lived intangible impairment review is completed in the fourth quarter of each year. Fair value for indefinite lived intangible assets was estimated based on a “relief from royalty” or “excess earnings” discounted cash flow method, which contains numerous variables that are subject to change as business conditions change, and therefore could impact fair values in the future. The key assumptions used in determining fair value are sales growth, profitability margins, tax rates, discount rates and

14

royalty rates. The Company determined that the fair value of all indefinite lived intangible assets for each of the years in the three-year period ended December 31, 2021 exceeded their respective carrying values based upon the forecasted cash flows and profitability.

Recently, the Company’s global FLAWLESS business has experienced declining customer demand for many of its products, primarily due to lower consumer spending for discretionary products from inflation. In addition, the FLAWLESS business has also started to experience margin contraction as the Company has been unable to implement price increases in a highly competitive category to offset higher labor, material and transportation costs. These factors have resulted in a reduction in expected future cash flows that, if these factors persist or continue to worsen, may result in cash flows that are not sufficient to recover the carrying value of the long-lived assets of the business. The projected cash flows exceed the carrying value of the long lived assets by slightly more than 10%. The key assumptions used to determine the projected cash flows include revenue, gross margin and marketing expense assumptions based on recent trends, including the reduction in customer demand for discretionary products and declining gross margins that FLAWLESS has been experiencing. The carrying value of the long-lived assets for the FLAWLESS business is approximately $465.0 at September 30, 2022. These assets are being amortized over their remaining weighted average life of 16 years. The long-lived assets of the FLAWLESS business are susceptible to impairment risk based on the factors described above. While management can and has implemented strategies to address the risk, including lowerin g the Company’s production costs, investing in new product ideas, and developing new creative advertising, significant adverse changes in demand, operating plans or economic factors in the future could reduce the underlying cash flows that could trigger a future impairment charge.

In recent years the Company’s TROJAN® business, specifically the condom category, has not grown and competition has increased. Social distancing requirements due to the COVID-19 pandemic had further negatively impacted the business. As a result, the TROJAN business had experienced stagnant sales and profits resulting in a reduction in expected future cash flows which eroded a portion of the excess between the fair and carrying value of the tradename. This indefinite-lived intangible asset may be susceptible to impairment risk and a continued decline in fair value could trigger a future impairment charge of the TROJAN tradename. The carrying value of the TROJAN tradename is $176.4 and fair value exceeded carrying value by 70% as of October 1, 2021. The key assumptions used in the projections from the Company’s October 1, 2021 impairment analysis include discount rates of 7.0% in the U.S. and 8.5% internationally, revenue assumptions based on recent trends, and an average royalty rate of approximately 10%. While management has implemented strategies to address the risk, including lowering production costs, investing in new product ideas, and developing new creative advertising, significant changes in operating plans or adverse changes in the future could reduce the underlying cash flows used to estimate fair value. More recently, TROJAN has experienced a recovery in sales and profits as it has benefited from an easing of COVID-19 social restrictions which led to an increase in sexual activity. The Company expects this trend will continue with the adoption of vaccines, the reduction of social distancing restrictions and the benefit of management strategies to improve sales and profitability.

The Company’s Passport Food Safety business has experienced sales and profit declines due to decreased demand driven by the COVID-19 pandemic and pressures from new competitive activities resulting from the loss of exclusivity on a key product line. In the fourth quarter of 2021, management’s review of the outlook for the Passport business indicated an assessment of the recoverability of the long-lived assets associated with the business was necessary. That review determined that the estimated future cash flows would not be sufficient to recover the carrying value of the assets resulting in an impairment of the associated tradename and other intangible assets of $11.3 in the fourth quarter of 2021. The charge was recorded in selling, general and administrative expenses. The assets have a current net book value of approximately $8.5 and are being amortized over their remaining weighted average life of 6 years. The Company is implementing strategies to address the decline in profitability. However, if unsuccessful, this decline could trigger an additional future impairment char ge.

The carrying amount of goodwill is as follows:

| Consumer |  |  | Consumer |  |  | Specialty |  |  |  |
| Domestic |  |  | International |  |  | Products |  |  | Total |
Balance at December 31, 2021 | $ | 1,899.8 |  |  | $ | 238.7 |  |  | $ | 136.0 |  |  | $ | 2,274.5 |
TheraBreath adjustment |  | 0.5 |  |  |  | (4.3 | ) |  |  | 0.0 |  |  |  | (3.8 | )
Balance at September 30, 2022 | $ | 1,900.3 |  |  | $ | 234.4 |  |  | $ | 136.0 |  |  | $ | 2,270.7 |

The result of the Company’s annual goodwill impairment test, performed in the beginning of the second quarter of 2022, determined that the estimated fair value substantially exceeded the carrying values of all reporting units. The determination of fair value contains numerous variables that are subject to change as business conditions change and therefore could impact fair value in the future. The Company has never incurred a goodwill impairment charge.

15

12.
Leases

The Company leases certain manufacturing facilities, warehouses, office space, railcars and equipment. Leases with an initial term of twelve months or less are not recorded on the condensed consolidated balance sheet. All recorded leases are classified as operating leases and lease expense is recognized on a straight-line basis over the lease term. For leases beginning in 2019, lease components (base rental costs) are accounted for separately from the nonlease components (e.g., common-area maintenance costs). For leases that do not provide an implicit rate, the Company uses its estimated secured incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments.

A summary of the Company’s lease information is as follows:

|  | September 30, |  | December 31, |
| Classification | 2022 |  | 2021 |
Assets |  |  |  |  |
Right of use assets | Other Assets | $ | 166.7 |  | $ | 159.4 |
Liabilities |  |  |  |  |
Current lease liabilities | Accounts Payable and Accrued Expenses | $ | 22.8 |  | $ | 24.4 |
Long-term lease liabilities | Deferred and Other Long-term Liabilities |  | 155.5 |  |  | 146.6 |
Total lease liabilities |  | $ | 178.3 |  | $ | 171.0 |
Other information |  |  |  |  |
Weighted-average remaining lease term (years) |  |  | 9.1 |  |  | 9.1 |
Weighted-average discount rate |  |  | 4.4 | % |  | 4.3 | %

| Three Months |  |  | Three Months |  |  | Nine Months |  |  | Nine Months |
| Ended |  |  | Ended |  |  | Ended |  |  | Ended |
| September 30, 2022 |  |  | September 30, 2021 |  |  | September 30, 2022 |  |  | September 30, 2021 |
Statement of Income |  |  |  |  |  |  |  |  |  |  |
Lease cost(1) | $ | 7.7 |  |  | $ | 8.1 |  |  | $ | 23.1 |  |  | $ | 24.6 |
Other information |  |  |  |  |  |  |  |  |  |  |
Leased assets obtained in exchange for new lease liabilities net of modifications(2) | $ | 9.5 |  |  | $ | 0.4 |  |  | $ | 26.8 |  |  | $ | 4.5 |
Cash paid for amounts included in the measurement of lease liabilities | $ | 7.8 |  |  | $ | 8.0 |  |  | $ | 23.3 |  |  | $ | 24.5 |

(1)
Lease expense is included in cost of sales or SG&A expenses based on the nature of the leased item. Short-term lease expense is excluded from this amount and is not material. The Company also has certain variable leases which are not material. The non-cash component of lease expense for the first nine months of 2022 and 2021 was $18.0 and $19.1, respectively, and is included in the Amortization caption in the condensed consolidated statement of cash flows.
(2)
In September 2022, the Company amended its contract at one of its international locations. This resulted in an increase to the Company’s right of use assets and corresponding lease liabilities of approximately $8.2 recorded in the third quarter of 2022. In June 2022, the Company amended its contract at one of its leased manufacturing facilities. This resulted in an increase to the Company’s right of use assets and corresponding lease liabilities of approximately $15.2 recorded in the second quarter of 2022.

16

The Company’s minimum annual rentals including reasonably assured renewal options under lease agreements are as follows:

|  | Operating |
|  | Leases |
2022 |  | $ | 8.1 |
2023 |  |  | 28.6 |
2024 |  |  | 27.2 |
2025 |  |  | 26.1 |
2026 |  |  | 18.7 |
2027 and thereafter |  |  | 112.1 |
Total future minimum lease commitments |  |  | 220.8 |
Less: Imputed interest |  |  | (42.5 | )
Present value of lease liabilities |  | $ | 178.3 |

13.
Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consist of the following:

| September 30, |  |  | December 31, |
| 2022 |  |  | 2021 |
Trade accounts payable | $ | 655.6 |  |  | $ | 663.8 |
Accrued marketing and promotion costs |  | 196.3 |  |  |  | 201.6 |
Accrued wages and related benefit costs |  | 52.5 |  |  |  | 87.7 |
Other accrued current liabilities |  | 127.6 |  |  |  | 166.6 |
Total | $ | 1,032.0 |  |  | $ | 1,119.7 |

17

14.
Short-Term Borrowings and Long-Term Debt

Short-term borrowings and long-term debt consist of the following:

|  | September 30, |  |  | December 31, |
|  | 2022 |  |  | 2021 |
Short-term borrowings |  |  |  |  |  |
Commercial paper issuances |  | $ | 0.0 |  |  | $ | 249.7 |
Various debt due to international banks |  |  | 3.3 |  |  |  | 3.1 |
Total short-term borrowings |  | $ | 3.3 |  |  | $ | 252.8 |
Long-term debt |  |  |  |  |  |
2.45% Senior notes due August 1, 2022 |  |  | 0.0 |  |  |  | 300.0 |
2.875% Senior notes due October 1, 2022(1) |  |  | 400.0 |  |  |  | 400.0 |
Less: Discount |  |  | 0.0 |  |  |  | (0.1 | )
Term loan due December 22, 2024 |  |  | 400.0 |  |  |  | 400.0 |
3.15% Senior notes due August 1, 2027 |  |  | 425.0 |  |  |  | 425.0 |
Less: Discount |  |  | (0.2 | ) |  |  | (0.3 | )
2.3% Senior notes due December 15, 2031 |  |  | 400.0 |  |  |  | 400.0 |
Less: Discount |  |  | (0.8 | ) |  |  | (0.8 | )
3.95% Senior notes due August 1, 2047 |  |  | 400.0 |  |  |  | 400.0 |
Less: Discount |  |  | (2.4 | ) |  |  | (2.5 | )
5.00% Senior notes due June 15, 2052 |  |  | 500.0 |  |  |  | 0.0 |
Less: Discount |  |  | (0.2 | ) |  |  | 0.0 |
Debt issuance costs, net |  |  | (17.0 | ) |  |  | (11.2 | )
Total long-term debt |  |  | 2,504.4 |  |  |  | 2,310.1 |
Less: Current maturities |  |  | (400.0 | ) |  |  | (699.4 | )
Net long-term debt |  | $ | 2,104.4 |  |  | $ | 1,610.7 |

(1) In October 2022, the Company repaid the full amount of the 2.875% Senior Notes due October 1, 2022 with a portion of the proceeds from the 5.00% Senior notes issued on June 2, 2022 and due June 15, 2052 and cash on hand.

New Credit Agreement

On June 16, 2022, the Company entered into a credit agreement (the “Credit Agreement”) that provides for a $1,500.0 unsecured revolving credit facility (the “Revolving Credit Facility”) that matures on June 16, 2027, unless extended. The Credit Agreement replaced the Company’s prior $1,000.0 unsecured revolving credit facility maturing on March 29, 2024 that was entered into on March 29, 2018. The Company continues to have the ability to increase its borrowing up to an additional $750.0, subject to lender commitments and certain conditions as described in the Credit Agreement. Borrowings under the Credit Agreement are available for general corporate purposes and are used to support the Company's $1,000.0 commercial paper program.

5.00% Senior Notes due June 15, 2052

On June 2, 2022, the Company issued $500.0 aggregate principal amount of 5.00% Senior Notes due 2052 (the “2052 Notes”). The 2052 Notes were issued under the second supplemental indenture (the “Second Supplemental Indenture”), dated June 2, 2022, to the indenture dated December 10, 2021 (the “Indenture”). In July 2022 a portion of the proceeds from the sale of the Notes were used to repay all of the Company's outstanding $300.0 2.45% Senior Notes due August 1, 2022. The remaining proceeds were used to pay a portion of the Company's $400.0 outstanding 2.875% Senior Notes due October 1, 2022. The 2052 Notes will mature on June 15, 2052, unless earlier retired or redeemed pursuant to the terms of the Second Supplemental Indenture.

18

15.
Accumulated Other Comprehensive Income (Loss)

The components of changes in accumulated other comprehensive income (loss) are as follows:

|  |  |  |  |  |  |  |  |  | Accumulated |
| Foreign |  |  | Defined |  |  |  |  |  | Other |
| Currency |  |  | Benefit |  |  | Derivative |  |  | Comprehensive |
| Adjustments |  |  | Plans |  |  | Agreements |  |  | Income (Loss) |
Balance at December 31, 2020 | $ | (26.4 | ) |  | $ | 0.0 |  |  | $ | (51.2 | ) |  | $ | (77.6 | )
Other comprehensive income (loss) before reclassifications |  | (4.7 | ) |  |  | (0.9 | ) |  |  | 32.4 |  |  |  | 26.8 |
Amounts reclassified to consolidated statement of income (a) (b) |  | 0.0 |  |  |  | 0.0 |  |  |  | (2.9 | ) |  |  | (2.9 | )
Tax benefit (expense) |  | 0.0 |  |  |  | 0.2 |  |  |  | (7.4 | ) |  |  | (7.2 | )
Other comprehensive income (loss) |  | (4.7 | ) |  |  | (0.7 | ) |  |  | 22.1 |  |  |  | 16.7 |
Balance at September 30, 2021 | $ | (31.1 | ) |  | $ | (0.7 | ) |  | $ | (29.1 | ) |  | $ | (60.9 | )
Balance at December 31, 2021 | $ | (30.2 | ) |  | $ | (0.6 | ) |  | $ | (37.4 | ) |  | $ | (68.2 | )
Other comprehensive income (loss) before reclassifications |  | (27.8 | ) |  |  | 2.5 |  |  |  | 66.1 |  |  |  | 40.8 |
Amounts reclassified to consolidated statement of income (a) (b) |  | 0.0 |  |  |  | 0.0 |  |  |  | (1.2 | ) |  |  | (1.2 | )
Tax benefit (expense) |  | 0.0 |  |  |  | (0.6 | ) |  |  | (16.9 | ) |  |  | (17.5 | )
Other comprehensive income (loss) |  | (27.8 | ) |  |  | 1.9 |  |  |  | 48.0 |  |  |  | 22.1 |
Balance at September 30, 2022 | $ | (58.0 | ) |  | $ | 1.3 |  |  | $ | 10.6 |  |  | $ | (46.1 | )

(a)
Amounts reclassified to cost of sales, selling, general and administrative expenses or interest expense.
(b)
The Company reclassified a gain of $0.9 and a gain of $2.5 to the condensed consolidated statements of income during the three months ended September 30, 2022 and 2021, respectively.

16. Commitments, Contingencies and Guarantees

Commitments

a. The Company has a partnership with a supplier of raw materials that mines and processes sodium-based mineral deposits. The Company purchases the majority of its sodium-based raw material requirements from the partnership. The partnership agreement terminates upon two years’ written notice by either partner. Under the partnership agreement, the Company has an annual commitment to purchase 240,000 tons of sodium-based raw materials at the prevailing market price. The Company is not engaged in any other material transactions with the partnership or the partner supplier.

b. As of September 30, 2022, the Company had commitments of approximately $314.1. These commitments include the purchase of raw materials, packaging supplies and services from its vendors at market prices to enable the Company to respond quickly to changes in customer orders or requirements, as well as costs associated with licensing and promotion agreements.

c. As of September 30, 2022, the Company had various guarantees and letters of credit totaling $5.0.

d. In connection with the Flawless Acquisition, the Company was obligated to pay an additional amount of up to $425.0 based on sales performance through 2021. The initial fair value of this business acquisition liability, established in the purchase price allocation, was $182.0. During the years ended December 31, 2021 and 2020, the Company decreased the fair value of the business acquisition liability by $98.0 and by $94.0, respectively, based on updated sales forecasts. As a result of these adjustments, the fair value of this business acquisition liability was $0.0 as of December 31, 2021, which was the end of the earn-out period. The changes in fair value were recorded in SG&A within the Consumer Domestic and Consumer International segment s.

In connection with the Zicam Acquisition, which was acquired on December 1, 2020, the Company deferred an additional cash payment of $20.0 related to certain indemnifications provided by the seller. Any amount that may be due is payable five years from the closing.

In connection with the TheraBreath Acquisition, which was acquired on December 21, 2021, the Company deferred an additional cash payment of $14.0 related to certain indemnity obligations provided by the seller. The additional amount, to the extent not used in satisfaction of such indemnity obligations, is payable in installments between two and four years from the closin g.

19

Legal proceedings

e. In conjunction with the Company’s acquisition and divestiture activities, the Company entered into select guarantees and indemnifications of performance with respect to the fulfillment of the Company’s commitments under applicable purchase and sale agreements. The arrangements generally indemnify the buyer or seller for damages associated with breach of contract, inaccuracies in representations and warranties surviving the closing date and satisfaction of liabilities and commitments retained under the applicable contract. Representations and warranties that survive the closing date generally survive for periods up to five years or the expiration of the applicable statutes of limitations. Potential losses under the indemnifications are generally limited to a portion of the original transaction price, or to other lesser specific dollar amounts for select provisions. With respect to sale transactions, the Company also routinely enters into non-competition agreements for varying periods of time. Guarantees and indemnifications with respect to acquisition and divestiture activities, if triggered, could have a materially adverse impact on the Company’s financial condition, results of operations and cash flows.

f. In addition to the matters described above, from time to time in the ordinary course of its business the Company is the subject of, or party to, various pending or threatened legal, regulatory or governmental actions or other proceedings, including, without limitation, those relating to, intellectual property, commercial transactions, product liability, purported consumer class actions, employment matters, antitrust, environmental, health, safety and other compliance related matters. Such proceedings are generally subject to considerable uncertainty and their outcomes, and any related damages, may not be reasonably predictable or estimable. Any such proceedings could result in a material adverse outcome negatively impacting the Company’s business, financial condition, results of operations or cash flows.

17.
Related Party Transactions

The following summarizes the balances and transactions between the Company and Armand Products Company (“Armand”) and The ArmaKleen Company (“ArmaKleen”), in each of which the Company holds a 50% ownership interest:

| Armand |  |  | ArmaKleen |
| Nine Months Ended |  |  | Nine Months Ended |
| September 30, |  |  | September 30, |  |  | September 30, |  |  | September 30, |
| 2022 |  |  | 2021 |  |  | 2022 |  |  | 2021 |
Purchases by Company | $ | 10.9 |  |  | $ | 9.8 |  |  | $ | 0.0 |  |  | $ | 0.0 |
Sales by Company | $ | 0.0 |  |  | $ | 0.0 |  |  | $ | 0.6 |  |  | $ | 0.8 |
Outstanding Accounts Receivable | $ | 0.5 |  |  | $ | 0.4 |  |  | $ | 0.9 |  |  | $ | 0.5 |
Outstanding Accounts Payable | $ | 1.6 |  |  | $ | 1.4 |  |  | $ | 0.0 |  |  | $ | 0.0 |
Administration & Management Oversight Services (1) | $ | 1.7 |  |  | $ | 1.6 |  |  | $ | 1.5 |  |  | $ | 1.5 |

(1)
Billed by the Company and recorded as a reduction of SG&A expenses.

18.
Segments

Segment Information

The Company operates three reportable segments: Consumer Domestic, Consumer International and Specialty Products Division. These segments are determined based on differences in the nature of products and organizational structure. The Company also has a Corporate segment.

Segment revenues are derived from the sale of the following products:

Segment |  |  | Products |
Consumer Domestic |  | Household and personal care products
Consumer International |  | Primarily personal care products
SPD |  | Specialty chemical products

20

The Corporate segment income consists of equity in earnings of affiliates. As of September 30, 2022, the Company held 50% ownership interests in each of Armand and ArmaKleen, respectively. The Company’s equity in earnings of Armand and ArmaKleen, totaling $3.7 and $2.0 for the three months ended September 30, 2022 and 2021, respectively, and $10.0 and $7.4 for the nine months ended September 30, 2022 and 2021, respectively, are included in the Corporate segment.

Certain subsidiaries that are included in the Consumer International segment manufacture and sell personal care products to the Consumer Domestic segment. These sales are eliminated from the Consumer International segment results set forth in the table below.

Segment net sales and income before income taxes are as follows:

| Consumer |  |  | Consumer |  |  |  |  |  |  |  |  |  |
| Domestic |  |  | International |  |  | SPD |  |  | Corporate(3) |  |  | Total |
Net Sales(1) |  |  |  |  |  |  |  |  |  |  |  |  |  |
Third Quarter 2022 | $ | 1,010.4 |  |  | $ | 219.7 |  |  | $ | 87.2 |  |  | $ | 0.0 |  |  | $ | 1,317.3 |
Third Quarter 2021 |  | 998.1 |  |  |  | 227.0 |  |  |  | 86.3 |  |  |  | 0.0 |  |  |  | 1,311.4 |
First Nine Months of 2022 | $ | 3,010.2 |  |  | $ | 664.8 |  |  | $ | 264.6 |  |  | $ | 0.0 |  |  | $ | 3,939.6 |
First Nine Months of 2021 |  | 2,900.2 |  |  |  | 670.2 |  |  |  | 251.0 |  |  |  | 0.0 |  |  |  | 3,821.4 |
Income before Income Taxes(2) |  |  |  |  |  |  |  |  |  |  |  |  |  |
Third Quarter 2022 | $ | 193.9 |  |  | $ | 22.7 |  |  | $ | 14.2 |  |  | $ | 3.7 |  |  | $ | 234.5 |
Third Quarter 2021(4) |  | 238.6 |  |  |  | 34.5 |  |  |  | 14.2 |  |  |  | 2.0 |  |  |  | 289.3 |
First Nine Months of 2022 | $ | 618.3 |  |  | $ | 80.8 |  |  | $ | 38.1 |  |  | $ | 10.0 |  |  | $ | 747.2 |
First Nine Months of 2021(4) |  | 713.7 |  |  |  | 110.9 |  |  |  | 35.6 |  |  |  | 7.4 |  |  |  | 867.6 |

(1)
Intersegment sales from Consumer International to Consumer Domestic, which are not reflected in the table, were $3.9 and $2.6 for the three months ended September 30, 2022 and September 30, 2021, respectively, and were $12.5 and $7.8 for the nine months ended September 30, 2022 and September 30, 2021, respectively.
(2)
In determining income before income taxes, interest expense, investment earnings and certain aspects of other income and expense were allocated among segments based upon each segment’s relative income from operations.
(3)
The Corporate segment consists of equity in earnings of affiliates from Armand and ArmaKleen for the three and nine months ended September 30, 2022 and September 30, 2021.
(4)
Results for the three months ended September 30, 2021 include a $41.0 reduction of SG&A expenses to adjust the Flawless business acquisition liability, of which $34.8 was recorded to Consumer Domestic and $6.2 was recorded to Consumer International. Results for the nine months ended September 30, 2021 include a $98.0 reduction of SG&A expenses to adjust the Flawless business acquisition liability, of which $83.2 was recorded to Consumer Domestic and $14.8 was recorded to Consumer International.

Product line revenues from external customers are as follows:

| Three Months Ended |  |  | Nine Months Ended |
| September 30, |  |  | September 30, |  |  | September 30, |  |  | September 30, |
| 2022 |  |  | 2021 |  |  | 2022 |  |  | 2021 |
Household Products | $ | 592.3 |  |  | $ | 535.5 |  |  | $ | 1,685.6 |  |  | $ | 1,553.7 |
Personal Care Products |  | 418.1 |  |  |  | 462.6 |  |  |  | 1,324.6 |  |  |  | 1,346.5 |
Total Consumer Domestic |  | 1,010.4 |  |  |  | 998.1 |  |  |  | 3,010.2 |  |  |  | 2,900.2 |
Total Consumer International |  | 219.7 |  |  |  | 227.0 |  |  |  | 664.8 |  |  |  | 670.2 |
Total SPD |  | 87.2 |  |  |  | 86.3 |  |  |  | 264.6 |  |  |  | 251.0 |
Total Consolidated Net Sales | $ | 1,317.3 |  |  | $ | 1,311.4 |  |  | $ | 3,939.6 |  |  | $ | 3,821.4 |

Household Products include laundry, deodorizing and cleaning products. Personal Care Products include condoms, pregnancy kits, oral care products, skin care and hair care products, cold and remedy products, and gummy dietary supplements.

21

19. Subsequent Event

On August 31, 2022, the Company entered into an Agreement and Plan of Merger pursuant to which the Company agreed to acquire all of the issued and outstanding shares of capital stock of Hero Cosmetics, Inc., the developer of the Hero Mighty Patch® brand and other acne treatment products (the “Hero Acquisition”). The total consideration related to the Hero Acquisition, which is subject to adjustment, consists of a purchase price of approximately $565.0 million of cash (of which $8.0 million will be held back for five years to satisfy certain indemnification obligations) and approximately $65.0 million of restricted shares of the Company's common stock which will be recognized as compensation expense as the stock is subject to vesting requirements for individuals who will continue to be employed by the Company. The Hero Acquisition closed on October 13, 2022 and was financed with cash on hand and commercial paper borrowings. The Company is in the process of completing the initial purchase price allocation for the acquisition which will primarily consist of acquired intangibles. As such, required disclosures will be presented in future periods.

22

CHURCH & DWIGHT CO., INC. AND SUBSIDIARIES

(In millions, except per share data)

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Recent Developments

Supply Chain, Inflation, Labor, Consumer Demand and Competition

Since the beginning of the COVID-19 pandemic, the impacts to our business have been primarily supply chain related, including labor shortages and challenges with distribution and transportation, resulting in difficulty meeting consumer demand and significant broad-based cost inflation. In addition, government restrictions in China have further exacerbated global supply chain challenges and have had a negative impact on Chinese consumer demand for our products in China. As restrictions in China ease, we expect those impacts to our business in the future to be less severe. While it is difficult to predict with certainty when conditions may improve, we expect shortages and input cost inflation to continue at least throughout 2022.

To address challenges meeting customer demand for certain categories, including laundry detergent and litter, we have taken steps to increase our short-term manufacturing capacity for many of our products as well as our raw material and packaging capacity, and continue to work closely with our suppliers, contract manufacturers and retail partners to increase capacity and ensure sustained supply to keep pace with increased demand. We have also made investments in the expansion of long-term, in-house and third-party manufacturing capacity and are working to enlist additional suppliers that meet our quality specifications. While there is no assurance that these challenges will abate in the foreseeable future, or that the other measures we have or may implement will mitigate the impact of supply disruptions or rising costs, we continued to see an improvement in fill rates in the third quarter, particularly in the household category, and we expect those improvements to continue through the remainder of 2022 across most product categories.

To attempt to offset some of our cost pressures, we have enacted and continue to evaluate price increases in certain categories. However, we are also experiencing a decline in consumer spending for our most discretionary brands, Waterpik and Flawless, and a consumer shift to lower cost alternatives due primarily to inflationary and recessionary pressures. Most notably, a growing number of water flosser consumers have switched to more value-branded products. To address these demand shifts, we are taking steps to better manage production schedules and inventory levels for those products along with increasing promotional activities and marketing spend, as well as continuing efforts to develop lower cost water flosser alternatives. Our portfolio being comprised of 40% value products and our low exposure to private label should help us to mitigate against a potential recessionary environment. We expect share gains to continue as we invest in our brands and supply chain fill levels continue to improve.

In the vitamin category there continues to be a softening of growth from record high levels during the COVID-19 pandemic and significant product competition coming from new category entrants. The category has grown from about 10 competitors a decade ago to more than 50 of significance in recent years. Since 2019 alone, over 35 new brands have entered the gummy segment category. We continue to evaluate and vigorously combat these pressures through, among other things, new product introductions and increased marketing and trade spending. However, there is no assurance this category will not decline in the future and that we will be able to offset any such decline.

Looking forward, the impact that these challenges will continue to have on our operational and financial performance will depend on future developments, including inflationary impacts, customer’s acceptance of all or a portion of any price increases, our continued ability to obtain an adequate supply of products and materials, the spread and severity of new COVID-19 variants, and the long-term impact of vaccines. Additionally, we may be impacted by our ability to recruit and retain a workforce and engage third-parties to manufacture and distribute our products, as well as any future government actions affecting employers and employees, consumers and the economy in general. The impact of any of these potential future developments are uncertain and difficult to predict considering the rapidly evolving landscape.

We are monitoring the impact of both inflation and recessionary indicators including the effect of corresponding government actions, such as raising interest rates to counteract inflation, that may negatively impact consumer spending, and how these factors will potentially influence future cash flows for the short and long term. While we expect that many of these effects will be transitory and that our value focused portfolio positions us well in inflationary and slowing economic environments, it is impossible to predict their impact.

23

Russia - Ukraine War

The global economy continues to be negatively impacted by the military conflict between Russia and Ukraine. Furthermore, governments in the U.S., United Kingdom, and European Union have each imposed export controls on certain products as well as financial and economic sanctions on certain industry sectors and parties in Russia and Belarus. We have experienced shortages in materials and increased costs for transportation, energy, and raw material due in part to the negative impact of the Russia-Ukraine military conflict on the global economy including European energy market access to Russian energy sources. Further escalation of geopolitical tensions related to the conflict, including increased trade barriers or restrictions on global trade, could result in, among other things, cyber attacks, supply disruptions, lower consumer demand, and changes to foreign exchange rates and financial markets, any of which may adversely affect our business and supply chain.

We have no operations in Russia or Ukraine. Sales into Russia and Belarus, which have been suspended indefinitely, are not material to the Company’s consolidated net sales and earnings.

Acquisition of Hero

On August 31, 2022, the Company entered into an Agreement and Plan of Merger pursuant to which the Company agreed to acquire all of the issued and outstanding shares of capital stock of Hero Cosmetics, Inc., the developer of the Hero Mighty Patch® brand and other acne treatment products (the “Hero Acquisition”). The total consideration related to the Hero Acquisition, which is subject to adjustment, consists of a purchase price of approximately $565.0 million of cash (of which $8.0 million will be held back for five years to satisfy certain indemnification obligations) and approximately $65.0 million of restricted shares of the Company's common stock which will be recognized as compensation expense as the stock is subject to vesting requirements for individuals who will continue to be employed by the Company. The Hero Acquisition closed on October 13, 2022 and was financed with cash on hand and commercial paper borrowings.

Inflation Reduction Act of 2022

On August 16, 2022, President Biden signed into law the Inflation Reduction Act of 2022 (the “Act”), which contains provisions effective January 1, 2023, including a 15% corporate minimum tax and a 1% excise tax on stock buybacks. While we are still evaluating the impact of the Act, we do not expect any material changes on our consolidated financial position, results of operations and cash flows.

24

Results of Operations

Consolidated results

| Three Months Ended |  |  | Change vs. |  | Three Months Ended |
| September 30, 2022 |  |  | Prior Year |  | September 30, 2021 |
Net Sales | $ | 1,317.3 |  |  | 0.4% |  | $ | 1,311.4 |
Gross Profit | $ | 549.7 |  |  | -5.1% |  | $ | 579.2 |
Gross Margin |  | 41.7 | % |  | -250 basis points |  |  | 44.2 | %
Marketing Expenses | $ | 140.7 |  |  | -12.6% |  | $ | 160.9 |
Percent of Net Sales |  | 10.7 | % |  | -160 basis points |  |  | 12.3 | %
Selling, General & Administrative Expenses | $ | 155.1 |  |  | 32.7% |  | $ | 116.9 |
Percent of Net Sales |  | 11.7 | % |  | 280 basis points |  |  | 8.9 | %
Income from Operations | $ | 253.9 |  |  | -15.8% |  | $ | 301.4 |
Operating Margin |  | 19.3 | % |  | -370 basis points |  |  | 23.0 | %
Net income per share - Diluted | $ | 0.76 |  |  | -17.4% |  | $ | 0.92 |
| Nine Months Ended |  |  | Change vs. |  | Nine Months Ended |
| September 30, 2022 |  |  | Prior Year |  | September 30, 2021 |
Net Sales | $ | 3,939.6 |  |  | 3.1% |  | $ | 3,821.4 |
Gross Profit | $ | 1,647.5 |  |  | -2.1% |  | $ | 1,682.3 |
Gross Margin |  | 41.8 | % |  | -220 basis points |  |  | 44.0 | %
Marketing Expenses | $ | 345.5 |  |  | -8.3% |  | $ | 376.6 |
Percent of Net Sales |  | 8.8 | % |  | -110 basis points |  |  | 9.9 | %
Selling, General & Administrative Expenses | $ | 505.8 |  |  | 25.5% |  | $ | 403.0 |
Percent of Net Sales |  | 12.8 | % |  | 230 basis points |  |  | 10.5 | %
Income from Operations | $ | 796.2 |  |  | -11.8% |  | $ | 902.7 |
Operating Margin |  | 20.2 | % |  | -340 basis points |  |  | 23.6 | %
Net income per share - Diluted | $ | 2.35 |  |  | -12.3% |  | $ | 2.68 |

Diluted Net Income per share was $0.76 in the third quarter of 2022 as compared to $0.92 in the third quarter of 2021. Diluted Net Income per share was $2.35 in the first nine months of 2022 as compared to $2.68 in the same period in 2021.

During the third quarter of 2021 we decreased the fair value of our business acquisition liability associated with the 2019 acquisition of the FLAWLESS hair removal business (the “Flawless Acquisition”) by $41.0 ($30.8 after tax or $0.12 diluted per share), for a total net reduction of $98.0 ($73.5 after tax or $0.29 diluted per share) for the nine months ended September 30, 2021, based on updated sales forecasts. After giving effect to the third quarter decrease, the value of the business acquisition liability was reduced to $0.0. The business acquisition liability adjustments were recorded as a reduction in SG&A expense.

25

Net Sales

Net sales for the quarter ended September 30, 2022 were $1,317.3, an increase of $5.9 or 0.4% as compared to the same period in 2021. Net sales for the nine months ended September 30, 2022 were $3,939.6, an increase of $118.2 or 3.1% over the comparable nine month period of 2021. The components of the net sales increase are as follows:

|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 30, |  |  | September 30, |
Net Sales - Consolidated |  | 2022 |  |  | 2022 |
Product volumes sold |  |  | (8.5 | )% |  |  | (5.6 | )%
Pricing/Product mix |  |  | 7.8 | % |  |  | 7.4 | %
Foreign exchange rate fluctuations |  |  | (1.2 | )% |  |  | (0.9 | )%
Acquired product lines (1) |  |  | 2.3 | % |  |  | 2.2 | %
Net Sales increase |  |  | 0.4 | % |  |  | 3.1 | %

(1)
On December 24, 2021, we acquired all of the outstanding equity of Dr. Harold Katz, LLC and HK-IP International, Inc., the owners of the THERABREATH brand of oral care products (the “TheraBreath Acquisition”). The results of this acquisition are included in our results since the date of acquisition.

For both the three and nine months ended September 30, 2022, the volume change reflects decreased product unit sales for all three segments. For both the three and nine months ended September 30, 2022, price/mix was favorable in all three segments.

Gross Profit / Gross Margin

Our gross profit was $549.7 for the three months ended September 30, 2022, a $29.5 decrease as compared to the same period in 2021. Gross margin decreased 250 basis points (“bps”) in the third quarter of 2022 compared to the same period in 2021, due to the impact of higher manufacturing costs including labor of 300 bps, higher commodities of 250 bps, and higher transportation costs of 30 bps, offset by favorable price/volume/mix of 190 bps, the impact of productivity programs of 120 bps, and business acquisition benefits of 20 bps. Gross profit was $1,647.5 for the nine months ended September 30, 2022, a $34.8 decrease compared to the same period in 2021. Gross margin decreased 220 bps in the first nine months of 2022 compared to the same period in 2021, due to the impact of higher manufacturing costs including labor of 260 bps, higher commodities of 250 bps, and higher transportation costs of 70 bps, offset by favorable price/volume/mix of 240 bps, the impact of productivity programs of 100 bps, and business acquisition benefits of 20 bps.

Operating Expenses

Marketing expenses for the three months ended September 30, 2022 were $140.7, a decrease of $20.2 or 12.6% as compared to the same period in 2021. Marketing expenses as a percentage of net sales in the third quarter of 2022 decreased by 160 bps to 10.7% as compared to 12.3% in the same period in 2021 due to 150 bps on lower expenses, and 10 bps of leverage on higher net sales. Marketing expenses for the nine months ended September 30, 2022 were $345.5, a decrease of $31.1 or 8.3% as compared to the same period in 2021. Marketing expenses as a percentage of net sales for the first nine months of 2022 decreased by 110 bps to 8.8% as compared to 9.9% in the same period in 2021 due to 80 bps on lower expenses and 30 bps of leverage on higher net sales.

SG&A expenses were $155.1 in the third quarter of 2022, an increase of $38.2 or 32.7% as compared to the same period in 2021. SG&A as a percentage of net sales increased 280 bps to 11.7% in the third quarter of 2022 as compared to 8.9% in the same period in 2021. The increase is due to 290 bps on higher expenses, offset by 10 bps of leverage associated with higher sales. The higher expenses for the three-month period ended September 30, 2022 are due to the prior year reduction in the fair value of the Flawless business acquisition liability of $41.0 which reduced SG&A expenses in 2021. SG&A expenses for the first nine months of 2022 were $505.8, an increase of $102.8 or 25.5% as compared to the same period in 2021. SG&A as a percentage of net sales increased 230 bps to 12.8% in the first nine months of 2022 compared to 10.5% in 2021 due to 260 bps on higher expenses, offset by 30 bps of leverage associated with higher sales. The higher expenses for the nine-month period ended September 30, 2022 are primarily due to the prior year reduction in the fair value of the Flawless business acquisition liability of $98.0 which reduced SG&A expenses in 2021.

Other (income) expense, net was nominal for the three and nine months ended September 30, 2022 and 2021.

Interest expense for the three and nine months ended September 30, 2022 increased $10.3 and $18.1 to $23.7 and $59.6, respectively, as compared to the same periods in 2021, due to higher average debt outstanding and higher interest rates.

26

Income Taxes

The effective tax rate for the three months ended September 30, 2022 was 20.2%, compared to 20.4% in the same period in 2021.

The effective tax rate for the nine months ended September 30, 2022 was 22.6%, compared to 22.8% in the same period in 2021.

On August 16, 2022, President Biden signed into law the Inflation Reduction Act of 2022 (the “Act”), which contains provisions effective January 1, 2023, including a 15% corporate minimum tax and a 1% excise tax on stock buybacks. While we are still evaluating the impact of the Act, we do not expect any material changes on our consolidated financial position, results of operations and cash flows.

Segment results

We operate three reportable segments: Consumer Domestic, Consumer International and SPD. These segments are determined based on differences in the nature of products and organizational structure. We also have a Corporate segment.

Segment |  |  | Products |
Consumer Domestic |  | Household and personal care products
Consumer International |  | Primarily personal care products
SPD |  | Specialty chemical products

The Corporate segment income consists of equity in earnings of affiliates. As of September 30, 2022, we held 50% ownership interests in each of Armand Products Company (“Armand”) and The ArmaKleen Company (“ArmaKleen”), respectively. Our equity in earnings of Armand and ArmaKleen, totaling $3.7 and $2.0 for the three months ended September 30, 2022 and 2021, respectively, and $10.0 and $7.4 for the nine months ended September 30, 2022 and 2021, respectively, are included in the Corporate segment. Certain subsidiaries that are included in the Consumer International segment manufacture and sell personal care products to the Consumer Domestic segment. These sales are eliminated from the Consumer International segment results set forth below.

27

Segment net sales and income before income taxes for the three and nine months ended September 30, 2022 and September 30, 2021 are as follows:

| Consumer |  |  | Consumer |  |  |  |  |  |  |  |  |  |
| Domestic |  |  | International |  |  | SPD |  |  | Corporate(3) |  |  | Total |
Net Sales(1) |  |  |  |  |  |  |  |  |  |  |  |  |  |
Third Quarter 2022 | $ | 1,010.4 |  |  | $ | 219.7 |  |  | $ | 87.2 |  |  | $ | 0.0 |  |  | $ | 1,317.3 |
Third Quarter 2021 |  | 998.1 |  |  |  | 227.0 |  |  |  | 86.3 |  |  |  | 0.0 |  |  |  | 1,311.4 |
First Nine Months of 2022 | $ | 3,010.2 |  |  | $ | 664.8 |  |  | $ | 264.6 |  |  | $ | 0.0 |  |  | $ | 3,939.6 |
First Nine Months of 2021 |  | 2,900.2 |  |  |  | 670.2 |  |  |  | 251.0 |  |  |  | 0.0 |  |  |  | 3,821.4 |
Income before Income Taxes(2) |  |  |  |  |  |  |  |  |  |  |  |  |  |
Third Quarter 2022 | $ | 193.9 |  |  | $ | 22.7 |  |  | $ | 14.2 |  |  | $ | 3.7 |  |  | $ | 234.5 |
Third Quarter 2021(4) |  | 238.6 |  |  |  | 34.5 |  |  |  | 14.2 |  |  |  | 2.0 |  |  |  | 289.3 |
First Nine Months of 2022 | $ | 618.3 |  |  | $ | 80.8 |  |  | $ | 38.1 |  |  | $ | 10.0 |  |  | $ | 747.2 |
First Nine Months of 2021(4) |  | 713.7 |  |  |  | 110.9 |  |  |  | 35.6 |  |  |  | 7.4 |  |  |  | 867.6 |

(1)
Intersegment sales from Consumer International to Consumer Domestic, which are not reflected in the table, were $3.9 and $2.6 for the three months ended September 30, 2022 and September 30, 2021, respectively, and were $12.5 and $7.8 for the nine months ended September 30, 2022 and September 30, 2021, respectively.
(2)
In determining income before income taxes, interest expense, investment earnings and certain aspects of other income and expense were allocated among the segments based upon each segment’s relative income from operations.
(3)
Corporate segment consists of equity in earnings of affiliates from Armand and ArmaKleen for the three and nine months ended September 30, 2022 and September 30, 2021.
(4)
Results for the three months ended September 30, 2021 include a $41.0 reduction of SG&A expenses to adjust the Flawless business acquisition liability, of which $34.8 was recorded to Consumer Domestic and $6.2 was recorded to Consumer International. Results for the nine months ended September 30, 2021 include a $98.0 reduction of SG&A expenses to adjust the Flawless business acquisition liability, of which $83.2 was recorded to Consumer Domestic and $14.8 was recorded to Consumer International.

Product line revenues from external customers are as follows:

| Three Months Ended |  |  | Nine Months Ended |
| September 30, |  |  | September 30, |  |  | September 30, |  |  | September 30, |
| 2022 |  |  | 2021 |  |  | 2022 |  |  | 2021 |
Household Products | $ | 592.3 |  |  | $ | 535.5 |  |  | $ | 1,685.6 |  |  | $ | 1,553.7 |
Personal Care Products |  | 418.1 |  |  |  | 462.6 |  |  |  | 1,324.6 |  |  |  | 1,346.5 |
Total Consumer Domestic |  | 1,010.4 |  |  |  | 998.1 |  |  |  | 3,010.2 |  |  |  | 2,900.2 |
Total Consumer International |  | 219.7 |  |  |  | 227.0 |  |  |  | 664.8 |  |  |  | 670.2 |
Total SPD |  | 87.2 |  |  |  | 86.3 |  |  |  | 264.6 |  |  |  | 251.0 |
Total Consolidated Net Sales | $ | 1,317.3 |  |  | $ | 1,311.4 |  |  | $ | 3,939.6 |  |  | $ | 3,821.4 |

Household Products include laundry, deodorizing, and cleaning products. Personal Care Products include condoms, pregnancy kits, oral care products, skin care and hair care products, cold and remedy products, and gummy dietary supplements.

28

Consumer Domestic

Consumer Domestic net sales in the third quarter of 2022 were $1,010.4, an increase of $12.3 or 1.2% as compared to the same period in 2021. Consumer Domestic net sales for the nine months ended September 30, 2022 were $3,010.2, an increase of $110.0 or 3.8% as compared to the same period in 2021. The components of the net sales change are the following:

| Three Months Ended |  |  | Nine Months Ended |
| September 30, |  |  | September 30, |
Net Sales - Consumer Domestic | 2022 |  |  | 2022 |
Product volumes sold |  | (9.7 | )% |  |  | (6.7 | )%
Pricing/Product mix |  | 8.0 | % |  |  | 7.8 | %
Acquired product lines (1) |  | 2.9 | % |  |  | 2.7 | %
Net Sales increase |  | 1.2 | % |  |  | 3.8 | %

(1)
Includes the TheraBreath Acquisition since the date of acquisition.

The increase in net sales for the three months ended September 30, 2022, reflects the impact of the TheraBreath® Acquisition, and higher net sales in ARM & HAMMER® Liquid Detergent, OXICLEAN® Versatile Stain Remover, BATISTE® dry shampoo, and ARM & HAMMER® Cat Litter, offset by declines in VITAFUSION® and L’IL CRITTERS® gummy vitamins, FLAWLESS® Hair Removal Products and WATERPIK® Shower Heads. The increase in net sales for the nine-month period ending September 30, 2022, reflects the impact of the TheraBreath® Acquisition, and higher net sales in ARM & HAMMER® Liquid Detergent, OXICLEAN® Powder, ARM & HAMMER® Cat Litter, and BATISTE® dry shampoo, offset by declines in FLAWLESS® Hair Removal Products, WATERPIK® Shower Heads, and VITAFUSION® and L’IL CRITTERS® gummy vitamins.

Recently, the Company’s global FLAWLESS business has experienced declining customer demand for many of its products, primarily due to lower consumer spending for discretionary products from inflation. In addition, the FLAWLESS business has also started to experience margin contraction as the Company has been unable to implement price increases in a highly competitive category to offset higher labor, material and transportation costs. These factors have resulted in a reduction in expected future cash flows that, if these factors persist or continue to worsen, may result in cash flows that are not sufficient to recover the carrying value of the long-lived assets of the business. The projected cash flows exceed the carrying value of the long lived assets by slightly more than 10%. The key assumptions used to determine the projected cash flows include revenue, gross margin and marketing expense assumptions based on recent trends, including the reduction in customer demand for discretionary products and declining gross margins that FLAWLESS has been experiencing. The carrying value of the long-lived assets for the FLAWLESS business is approximately $465.0 at September 30, 2022. These assets are being amortized over their remaining weighted average life of 16 years. The long-lived assets of the FLAWLESS business are susceptible to impairment risk based on the factors described above. While management can and has implemented strategies to address the risk, including lowering the Company’s production costs, investing in new product ideas, and developing new creative advertising, significant adverse changes in demand, operating plans or economic factors in the future could reduce the underlying cash flows that could trigger a future impairment charge.

In recent years our TROJAN business, specifically the condom category, has not grown and competition has increased. Social distancing requirements due to the COVID-19 pandemic had further negatively impacted the business. As a result, the TROJAN business had experienced stagnant sales and profits resulting in a reduction in expected future cash flows which eroded a portion of the excess between the fair and carrying value of the tradename. This indefinite-lived intangible asset may be susceptible to impairment risk and a continued decline in fair value could trigger a future impairment charge of the TROJAN tradename. While management has implemented strategies to address the risk, including lowering our production costs, investing in new product ideas, and developing new creative advertising, significant changes in operating plans or adverse changes in the future could reduce the underlying cash flows used to estimate fair value. More recently, TROJAN has experienced a recovery in sales and profits as it has benefited from an easing of COVID-19 social restrictions which led to an increase in sexual activity. We expect this trend will continue with the adoption of vaccines, the reduction of social distancing restrictions and the benefit of management strategies to improve sales and profitabilit y.

29

Consumer Domestic income before income taxes for the third quarter of 2022 was $193.9, a $44.7 decrease as compared to the third quarter of 2021. The decrease is due primarily to the impact of lower sales volumes of $52.0, higher manufacturing and distribution expenses of $35.2, higher SG&A expenses of $31.2 (due to the prior year reduction in the fair value of the Flawless business acquisition liability of $34.8), and higher interest and other expenses of $7.9, partially offset by a favorable price/mix of $65.9 and lower marketing expenses of $14.7. For the nine-month period ended September 30, 2022, income before income taxes was $618.3, a $95.4 decrease as compared to the first nine months of 2021. The decrease is due primarily to higher manufacturing and distribution expenses of $127.2, higher SG&A expenses of $83.5 (due to the prior year reduction in the fair value of the Flawless business acquisition liability of $83.2), the impact of lower sales volumes of $80.6, and higher interest and other expenses of $14.7, partially offset by a favorable price/mix of $186.4 and lower marketing expenses of $22.8.

Consumer International

Consumer International net sales were $219.7 in the third quarter of 2022, a decrease of $7.3 or 3.2% as compared to the same period in 2021. Consumer International net sales in the first nine months of 2022 were $664.8, a decrease of $5.4 or 0.8% as compared to the same period in 2021. The components of the net sales change are the following:

| Three Months Ended |  |  | Nine Months Ended |
| September 30, |  |  | September 30, |
Net Sales - Consumer International | 2022 |  |  | 2022 |
Product volumes sold |  | (3.0 | )% |  |  | (1.0 | )%
Pricing/Product mix |  | 6.2 | % |  |  | 4.4 | %
Foreign exchange rate fluctuations |  | (7.1 | )% |  |  | (5.0 | )%
Acquired product lines (1) |  | 0.7 | % |  |  | 0.8 | %
Net Sales decrease |  | (3.2 | )% |  |  | (0.8 | )%

(1)
Includes the TheraBreath Acquisition since the date of acquisition.

Excluding the impact of foreign exchange rates, sales were higher in the third quarter ended September 30, 2022 for BATISTE, FLAWLESS, and FIRST RESPONSE in Australia, STERIMAR and TROJAN in Mexico, and BATISTE in Canada and Europe. The increase in net sales for the nine-month period ending September 30, 2022 is driven by CURASH and BATISTE in Australia, BATISTE, STERIMAR, and ARM & HAMMER Dental Care in Europe, VMS, BATISTE, OXICLEAN, and STERIMAR in GMG, and CAT LITTER, GRAVOL, and VMS in Canada.

Recently, the Company’s global FLAWLESS business has experienced declining customer demand for many of its products, primarily due to lower consumer spending for discretionary products from inflation. In addition, the FLAWLESS business has also started to experience margin contraction as the Company has been unable to implement price increases in a highly competitive category to offset higher labor, material and transportation costs. These factors have resulted in a reduction in expected future cash flows that, if these factors persist or continue to worsen, may result in cash flows that are not sufficient to recover the carrying value of the long-lived assets of the business. The projected cash flows exceed the carrying value of the long lived assets by slightly more than 10%. The key assumptions used to determine the projected cash flows include revenue, gross margin and marketing expense assumptions based on recent trends, including the reduction in customer demand for discretionary products and declining gross margins that FLAWLESS has been experiencing. The carrying value of the long-lived assets for the FLAWLESS business is approximately $465.0 at September 30, 2022. These assets are being amortized over their remaining weighted average life of 16 years. The long-lived assets of the FLAWLESS business are susceptible to impairment risk based on the factors described above. While management can and has implemented strategies to address the risk, including lowering the Company’s production costs, investing in new product ideas, and developing new creative advertising, significant adverse changes in demand, operating plans or economic factors in the future could reduce the underlying cash flows that could trigger a future impairment charge.

30

Consumer International income before income taxes was $22.7 in the third quarter of 2022, an $11.8 decrease as compared to the third quarter of 2021. Higher manufacturing and commodity costs of $11.2, higher SG&A expenses of $7.8 (primarily due to the prior year reduction in fair value of the Flawless business acquisition liability of $6.2), the impact of lower sales volumes of $3.1, unfavorable foreign exchange rates of $2.1, and higher interest and other expenses of $1.8, were partially offset by a favorable price/mix of $11.1 and lower marketing expenses of $3.0. For the first nine months of 2022, income before income taxes was $80.8, an $30.1 decrease as compared to the same period in 2021. Higher manufacturing and commodity costs of $21.3, higher SG&A expenses of $18.5 (primarily due to the prior year reduction in fair value of the Flawless business acquisition liability of $14.8), unfavorable foreign exchange rates of $6.2, the impact of lower sales volumes of $2.8, and higher interest and other expenses of $2.1, were partially offset by a favorable price/mix of $17.0 and lower marketing expenses of $3.6.

Specialty Products (“SPD”)

SPD net sales were $87.2 in the third quarter of 2022, an increase of $0.9 or 1.0% as compared to the same period in 2021. SPD net sales were $264.6 for the first nine months of 2022, an increase of $13.6, or 5.4% as compared to the same period in 2021. The components of the net sales change are the following:

| Three Months Ended |  |  | Nine Months Ended |
| September 30, |  |  | September 30, |
Net Sales - SPD | 2022 |  |  | 2022 |
Product volumes sold |  | (8.5 | )% |  |  | (5.0 | )%
Pricing/Product mix |  | 9.5 | % |  |  | 10.4 | %
Net Sales increase |  | 1.0 | % |  |  | 5.4 | %

Net sales increased in the three and nine months ended September 30, 2022 primarily due to higher pricing in our dairy and specialty chemicals segments in response to rising costs.

SPD income before income taxes was $14.2 in the third quarter of 2022, flat as compared to the same period in 2021 due to favorable price/product mix of $8.2, lower SG&A expenses of $0.6, and lower marketing costs of $0.2, offset by unfavorable manufacturing costs of $5.5, lower volumes of $2.9, and higher other expenses of $0.6. SPD income before income taxes was $38.1 in the first nine months of 2022, an increase of $2.5 as compared to the same period in 2021 due primarily to favorable price/product mix of $23.7, partially offset by unfavorable manufacturing costs of $19.6, higher other expenses of $1.4, higher SG&A costs of $0.2, and higher marketing expenses of $0.1.

Corporate

The Corporate segment includes equity in earnings of affiliates from Armand and ArmaKleen in the three and nine months of 2022 and 2021. The Corporate segment income before income taxes was $3.7 in the third quarter of 2022, as compared to $2.0 in the same period in 2021. The Corporate segment income before income taxes was $10.0 for the first nine months of 2022, as compared to $7.4 in the same period in 2021.

31

Liquidity and Capital Resources

On June 16, 2022, we entered into a credit agreement (the “Credit Agreement”) that provides for our $1,500.0 unsecured revolving credit facility (the “Revolving Credit Facility”) that matures on June 16, 2027, unless extended. The Credit Agreement replaced our prior $1,000.0 unsecured revolving credit facility maturing on March 29, 2024 that was entered into on March 29, 2018. We continue to have the ability to increase our borrowing up to an additional $750.0, subject to lender commitments and certain conditions as described in the Credit Agreement. Borrowings under the Credit Agreement are available for general corporate purposes and are used to support our $1,000.0 commercial paper program.

As of September 30, 2022, we had $437.6 in cash and cash equivalents, and approximately $1,496.0 available through the Revolving Credit Facility and our commercial paper program. To preserve our liquidity, we invest cash primarily in government money market funds, prime money market funds, short-term commercial paper and short-term bank deposits.

On June 2, 2022, we issued $500.0 aggregate principal amount of 5.00% Senior Notes due 2052 (the “2052 Notes”). The 2052 Notes were issued under the second supplemental indenture (the “Second Supplemental Indenture”), dated June 2, 2022, to the indenture dated December 10, 2021 (the “Indenture”). In July 2022 a portion of t he proceeds from the sale of the Notes were used to repay all of our outstanding $300.0 2.45% Senior Notes due August 1, 2022. The 2052 Notes will mature on June 15, 2052, unless earlier retired or redeemed pursuant to the terms of the Second Supplemental Indenture.

In October 2022, we repaid all of the outstanding $400.0 2.875% Senior notes due October 1, 2022 with a portion of the proceeds from the 5.00% Senior notes issued on June 2, 2022 and due June 15, 2052 and cash on hand.

The current economic environment presents risks that could have adverse consequences for our liquidity. See “Unfavorable economic conditions could adversely affect demand for our products” under “Risk Factors” in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “Form 10-K”). We continue to manage all aspects of our business including, but not limited to, monitoring the financial health of our customers, suppliers and other third-party relationships, implementing gross margin enhancement strategies and developing new opportunities for growth. We do not anticipate that current economic conditions will adversely affect our ability to comply with the financial covenant in the Credit Agreement because we currently are, and anticipate that we will continue to be, in compliance with the maximum leverage ratio requirement under the Credit Agreement.

On October 28, 2021, the Board authorized a new share repurchase program, under which we may repurchase up to $1,000.0 in shares of Common Stock (the “2021 Share Repurchase Program”). The 2021 Share Repurchase Program does not have an expiration and replaced the 2017 Share Repurchase Program. All remaining dollars authorized for repurchase under the 2017 Share Repurchase Plan have been cancelled. The 2021 Share Repurchase Program did not modify our evergreen share repurchase program, authorized by the Board on January 29, 2014, under which we may repurchase, from time to time, Common Stock to reduce or eliminate dilution associated with issuances of Common Stock under its incentive plans.

In December 2021, we executed open market purchases of 1.8 million shares for $170.3, inclusive of fees, of which $100.0 was purchased under the evergreen share repurchase program and $70.3 was purchased under the 2021 Share Repurchase Program. In December 2021, we also entered into an accelerated share repurchase ("ASR") contract with a commercial bank to purchase Common Stock. We paid $200.0 to the bank, inclusive of fees, and received an initial delivery of shares equal to $180.0, or 1.8 million. We used cash on hand and short-term borrowings to fund the initial purchase price. Upon the completion of the ASR, which ended in February 2022, the bank delivered an additional 0.2 million shares. The final shares delivered to us were determined by the average price per share paid by the bank during the purchase period. All 2.0 million shares were purchased under the 2021 Share Repurchase Program.

As a result of our recent stock repurchases, there remains $729.7 of share repurchase availability under the 2021 Share Repurchase Program as of September 30, 2022.

On January 28, 2022, the Board declared a 4% increase in the regular quarterly dividend from $0.2525 to $0.2625 per share, equivalent to an annual dividend of $1.05 per share. The increase raises the annual dividend payout from $248.0 to approximately $255.0. For the three and nine months ended September 30, 2022, we paid dividends of $63.8 and $191.2, respectively.

We anticipate that our cash from operations, together with our current borrowing capacity, will be sufficient to fund our share repurchase programs to the extent implemented by management, pay debt and interest as it comes due and pay dividends at the latest approved rate, and meet our capital expenditure program costs, which are expected to be approximately $170.0 in 2022 primarily for manufacturing capacity investments in laundry and litter to support expected future sales growth. Cash, together with our current borrowing capacity, may be used for acquisitions that would complement our existing product lines or geographic markets.

32

Cash Flow Analysis

| Nine Months Ended |
| September 30, |  |  | September 30, |
| 2022 |  |  | 2021 |
Net cash provided by operating activities | $ | 534.1 |  |  | $ | 653.6 |
Net cash used in investing activities | $ | (100.7 | ) |  | $ | (69.7 | )
Net cash used in financing activities | $ | (226.0 | ) |  | $ | (585.4 | )

Net Cash Provided by Operating Activities – Our primary source of liquidity is the cash flow provided by operating activities, which is dependent on net income and changes in working capital. Our net cash provided by operating activities in the nine months ended September 30, 2022 decreased by $119.5 to $534.1 as compared to $653.6 in the same period in 2021 due to an increase in working capital and lower cash earnings (net income adjusted for non-cash items). The increase in working capital is primarily related to higher inventory levels for Waterpik and Vitamins as well as raw materials to ensure adequate supply. We measure working capital effectiveness based on our cash conversion cycle. The following table presents our cash conversion cycle information for the quarters ended September 30, 2022 and 2021:

| As of |  |  |  |
| September 30, 2022 |  |  | September 30, 2021 |  |  | Change |
Days of sales outstanding in accounts receivable ("DSO") |  | 27 |  |  |  | 28 |  |  |  | (1 | )
Days of inventory outstanding ("DIO") |  | 79 |  |  |  | 68 |  |  |  | 11 |
Days of accounts payable outstanding ("DPO") |  | 78 |  |  |  | 73 |  |  |  | (5 | )
Cash conversion cycle |  | 28 |  |  |  | 23 |  |  |  | 5 |

Our cash conversion cycle (defined as the sum of DSO and DIO less DPO) which is calculated using a two-period average method, increased 5 days from the prior year as higher inventory levels for Waterpik and Vitamins, as well as raw materials, offset the benefit of payment term extensions. We continue to focus on reducing our working capital requirements.

Net Cash Used in Investing Activities – Net cash used in investing activities during the first nine months of 2022 was $100.7, primarily reflecting $98.1 property, plant and equipment additions. Net cash used in investing activities during the first nine months of 2021 was $69.7, primarily reflecting $64.1 for property, plant and equipment additions.

Net Cash Used in Financing Activities – Net cash used in financing activities during the first nine months of 2022 was $226.0 reflecting $191.2 of cash dividend payments, $49.7 of net debt repayments, and $7.5 of deferred financing costs, partially offset by $22.4 of proceeds from stock option exercises. Net cash used in financing activities during the first nine months of 2021 was $585.4, reflecting $371.6 of net debt payments, $185.8 of cash dividend payments, and $54.9 of treasury stock purchases, partially offset by $26.9 of proceeds from stock option exercises.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK

Market risk

For quantitative and qualitative disclosures about market risk affecting the Company, see “Quantitative and Qualitative Disclosures About Market Risk” in Item 7A of Part II in the Form 10-K.

ITEM 4. CONTROLS AND PROCEDURES

a) Evaluation of Disclosure Controls and Procedures

The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) at the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures, as of the end of the period covered by this report, are effective to provide reasonable assurance that the information required to be disclosed by the Company in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the rules and forms of the United States Securities and Exchange Commission (the “Commission”), and (ii) accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding the disclosure.

33

b) Change in Internal Control over Financial Reporting

There were no changes in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurring during the Company’s most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

CAUTIONARY NOTE ON FORWARD-LOOKING INFORMATION

This report contains forward-looking statements, including, among others, statements relating to net sales and earnings growth; the impact of the COVID-19 pandemic and the Company’s response; gross margin changes; trade and marketing spending; marketing expense as a percentage of net sales; sufficiency of cash flows from operations; earnings per share; the impact of new accounting pronouncements; cost savings programs; recessionary conditions, consumer demand and spending; the effects of competition; the effect of product mix; volume growth, including the effects of new product launches into new and existing categories; the decline of condom usage; the Company’s hedge programs; the impact of foreign exchange, tariffs, and commodity price fluctuations; impairments and other charges; the Company’s investments in joint ventures; the impact of acquisitions and divestitures; capital expenditures; the Company’s effective tax rate; the impact of tax audits; tax changes and the lapse of applicable statutes of limitations; the effect of the credit environment on the Company’s liquidity and capital resources; the Company’s fixed rate debt; compliance with covenants under the Company’s debt instruments; the Company’s commercial paper program; the Company’s current and anticipated future borrowing capacity to meet capital expenditure program costs; and the Company’s share repurchase programs; payment of dividends; environmental and regulatory matters; the availability and adequacy of raw materials, including trona reserves and the conversion of such reserves; and the customers and consumer acceptance of certain ingredients in our products. Other forward-looking statements in this report are generally identified by the use of such terms as “may,” “could,” “expect,” “intend,” “believe,” “plan,” “estimate,” “forecast,” “project,” “anticipate,” “to be,” “to make” or other comparable terms. These statements represent the intentions, plans, expectations and beliefs of the Company, and are based on assumptions that the Company believes are reasonable but may prove to be incorrect. In addition, these statements are subject to risks, uncertainties and other factors, many of which are outside the Company’s control and could cause actual results to differ materially from such forward-looking statements. Factors that could cause such differences include a decline in market growth, retailer distribution and consumer demand (as a result of, among other things, political, economic and marketplace conditions and events), including those relating to the outbreak of contagious diseases; other impacts of the COVID-19 pandemic and its impact on the Company’s operations, customers, suppliers, employees, and other constituents, and market volatility and impact on the economy (including causing recessionary conditions), resulting from global, nationwide or local or regional outbreaks or increases in infections, new variants, and the risk that the Company will not be able to successfully execute its response plans with respect to the pandemic or localized outbreaks and the corresponding uncertainty; the impact of regulatory changes or policies associated with the COVID-19 pandemic, including continuing or renewed shutdowns of retail and other businesses in various jurisdictions; the impact of the CARES Act and other governmental actions; the impact on the global economy of the military conflict between Russia and Ukraine, including the impact of export controls and other economic sanctions; the impact of continued shifts in consumer behavior, including accelerating shifts to on-line shopping; unanticipated increases in raw material and energy prices, including as a result of the military conflict between Russia and Ukraine; delays and increased costs in manufacturing and distribution; increases in transportation costs; labor shortages; the impact of price increases for our products; the impact of supply chain disruptions; the impact of inclement weather on raw material and transportation costs; adverse developments affecting the financial condition of major customers and suppliers; competition; changes in marketing and promotional spending; growth or declines in various product categories and the impact of customer actions in response to changes in consumer demand and the economy, including increasing shelf space or on-line share of private label and retailer-branded products or other changes in the retail environment; consumer and competitor reaction to, and customer acceptance of, new product introductions and features; the Company’s ability to maintain product quality and characteristics at a level acceptable to our customers and consumers; disruptions in the banking system and financial markets; foreign currency exchange rate fluctuations; implications of the United Kingdom’s withdrawal from the European Union; transition to, and shifting economic policies in the United States; potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs, including the actual and potential effect of tariffs on Chinese goods imposed by the United States; increased or changing regulation regarding the Company’s products in the United States and other countries where it or its suppliers operate; market volatility; issues relating to the Company’s information technology and controls; the impact of natural disasters, including those related to climate change, on the Company and its customers and suppliers, including third party information technology service providers; integrations of acquisitions or divestiture of assets; the outcome of contingencies, including litigation, pending regulatory proceedings and environmental matters; and changes in the regulatory environment.

The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the United States federal securities laws. You are advised, however, to

34

consult any further disclosures the Company makes on related subjects in its filings with the United States Securities and Exchange Commission (the “Commission”).

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

General

The Company, in the ordinary course of its business, is subject of, or party to, various pending or threatened legal actions, government investigations and proceedings from time to time, including, without limitation, those relating to commercial transactions, product liability, purported consumer class actions, employment matters, antitrust, environmental, health, safety and other compliance related matters. Such proceedings are subject to many uncertainties and the outcome of certain pending or threatened legal actions may not be reasonably predictable and any related damages may not be estimable. Certain legal actions could result in an adverse outcome for us, and any such adverse outcome could have a material adverse effect on our business, financial condition, results of operations, and cash flows.

ITEM 1A. RISK FACTORS

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Item 1A, “Risk Factors” in the Form 10-K, which could materially affect the Company’s business, financial condition or future results.

35

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Purchases of Equity Securities

The Company repurchases shares of its Common Stock from time to time pursuant to its publicly announced share repurchase programs.

During the third quarter of 2022 the Company did not repurchase any shares of Common Stock pursuant to its share repurchase programs.

On October 28, 2021, the Board authorized a new share repurchase program under which the Company may purchase up to $1,000.0 in shares of Common Stock (the “2021 Share Repurchase Program”). The 2021 Share Repurchase Program does not have an expiration and replaces the Company’s 2017 Share Repurchase Program. All remaining dollars authorized for repurchase under the 2017 Share Repurchase Plan have been cancelled. The 2021 Share Repurchase Program does not modify the Company’s evergreen share repurchase program, authorized by the Board on January 29, 2014, under which the Company may repurchase, from time to time, Common Stock to reduce or eliminate dilution associated with issuances of Common Stock under its incentive plans.

In December 2021, the Company executed open market purchases of 1.8 million shares for $170.3, inclusive of fees, of which $100.0 was purchased under the evergreen share repurchase program and $70.3 was purchased under the 2021 Share Repurchase Program. In December 2021, the Company also entered into an accelerated share repurchase ("ASR") contract with a commercial bank to purchase Common Stock. The Company paid $200.0 to the bank, inclusive of fees, and received an initial delivery of shares equal to $180.0, or 1.8 million shares. The Company used cash on hand and short-term borrowings to fund the initial purchase price. Upon the completion of the ASR, which ended in February 2022, the bank delivered an additional 0.2 million shares to the Company. The final shares delivered to the Company were determined by the average price per share paid by the bank during the purchase period. All 2.0 million shares were purchased under the 2021 Share Repurchase Program.

As a result of the Company’s recent stock repurchases, there remains $729.7 of share repurchase availability under the 2021 Share Repurchase Program as of September 30, 2022.

Sales of Unregistered Securities

On August 31, 2022, the Company entered into an Agreement and Plan of Merger (the “Hero Merger Agreement”) pursuant to which the Company agreed to acquire all of the issued and outstanding shares of capital stock of Hero Cosmetics, Inc., the developer of the Hero Mighty Patch® brand and other acne treatment products (the “Hero Acquisition”). The total consideration related to the Hero Acquisition, which is subject to adjustment, consists of approximately $565.0 million of cash (of which $8.0 million will be held back for five years to satisfy certain indemnification obligations) and approximately $65.0 million of restricted shares of the Company's common stock which will be recognized as compensation expense as the stock is subject to vesting requirements for individuals who will continue to be employed by the Company. The Hero Acquisition closed on October 13, 2022 and was financed with cash on hand and commercial paper borrowings. The Company issued an aggregate of 854,882 shares of restricted stock in the transaction which was exempt from registration by Section 4(a)(2) of the Securities Act of 1933, as amended and Regulation D thereunder.

36

ITE M 6. EXHIBITS

Exhibit Index

|  | (3.1) |  | Amended and Restated Certificate of Incorporation of the Company, incorporated by reference to Exhibit 3.1 to the Company’s quarterly report on Form 10-Q filed on June 30, 2020.
|  | (3.2) |  | Amendment to the Company’s Amended and Restated Certificate of Incorporation, incorporated by reference to Exhibit 3.1 to the Company’s current report on Form 8-K filed on April 30, 2021.
|  | (10.4) |  | First Amendment to Credit Agreement dated June 16, 2022, among Church & Dwight Co., Inc., the lenders named therein, and Bank of America, N.A., as administrative agent, incorporated by reference to Exhibit 10.2 to the Company’s current report on Form 8-K filed on June 21, 2022.
 |  | (31.1) |  | Certification of the Chief Executive Officer of the Company pursuant to Rule 13a-14(a) under the Securities Exchange Act.
 |  | (31.2) |  | Certification of the Chief Financial Officer of the Company pursuant to Rule 13a-14(a) under the Securities Exchange Act.
 |  | (32.1) |  | Certification of the Chief Executive Officer of the Company pursuant to Rule 13a-14(b) under the Exchange Act and 18 U.S.C. Section 1350.
 |  | (32.2) |  | Certification of the Chief Financial Officer of the Company pursuant to Rule 13a-14(b) under the Exchange Act and 18 U.S.C. Section 1350.
|  | (101.INS) |  | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
|  | (101.SCH) |  | Inline XBRL Taxonomy Extension Schema Document.
|  | (101.CAL) |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document.
|  | (101.DEF) |  | Inline XBRL Taxonomy Extension Definition Linkbase Document.
|  | (101.LAB) |  | Inline XBRL Taxonomy Extension Label Linkbase Document.
|  | (101.PRE) |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document.
|  | (104) |  | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

•
Indicates documents filed herewith.

37

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

|  |  |  | CHURCH & DWIGHT CO., INC.
|  |  |  | (REGISTRANT)
DATE: |  | October 28, 2022 |  | /s/ Richard A. Dierker
|  |  |  | RICHARD A. DIERKER
|  |  |  | Executive Vice President
|  |  |  | and Chief Financial Officer
|  |  |  | (Principal Financial Officer)
DATE: |  | October 28, 2022 |  | /s/ Joseph J. Longo
|  |  |  | JOSEPH J. LONGO
|  |  |  | VICE PRESIDENT AND
|  |  |  | CONTROLLER
|  |  |  | (PRINCIPAL ACCOUNTING OFFICER)

38